Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies | OLS miRNA effect size | OLS covariates effect size |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-miR-106b-5p | APC | 1.05 | 0.13909 | -0.54 | 0.25302 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 23087084 | miR 106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma; Moreover we demonstrated that miR-106b downregulates APC expression by directly targeting the 3'-untranslated region of APC messenger RNA; Taken together our results suggest that miR-106b plays an important role in promoting the proliferation of human hepatoma cells and presents a novel mechanism of micro RNA-mediated direct suppression of APC expression in cancer cells | -0.1 | type:-0.68, stage:-0.01, histology:0.02, PAM50:0.08, ER:-0.1, PR:-0.07, HER2:0.14, Triple_Negative:-0.41 |
| 2 | hsa-miR-107 | AXIN2 | 0.35 | 0.52382 | -1.13 | 0.00118 | miRTarBase; MirTarget; PITA; miRanda; miRNATAP | -0.31 | 0 | 26191213 | miR 107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2; At the molecular level our results suggested that expression of Axin2 was negatively regulated by miR-107; Our observations suggested that miR-107 could promote HCC cells proliferation via targeting Axin2 and might represent a potential therapeutic target for HCC | -0.11 | type:1.19, stage:-0.07, histology:0.02, PAM50:0.28, ER:0.52, PR:0.26, HER2:-0.03, Triple_Negative:0.17 |
| 3 | hsa-miR-15a-5p | AXIN2 | 0.34 | 0.60504 | -1.13 | 0.00118 | MirTarget; miRNATAP | -0.31 | 0 | 26252081 | The combination of miR-15a and AXIN2 significantly improved the diagnostic accuracy | -0.13 | type:1.19, stage:-0.07, histology:0.02, PAM50:0.27, ER:0.52, PR:0.26, HER2:-0.04, Triple_Negative:0.16 |
| 4 | hsa-miR-590-3p | AXIN2 | 1.01 | 0 | -1.13 | 0.00118 | MirTarget; PITA; miRanda; miRNATAP | -0.36 | 0 | NA | -0.04 | type:1.11, stage:-0.07, histology:0.02, PAM50:0.27, ER:0.52, PR:0.26, HER2:-0.03, Triple_Negative:0.15 | |
| 5 | hsa-miR-125a-5p | CAMK2A | -0.14 | 0.87179 | -0.12 | 0.63413 | mirMAP | -0.31 | 0 | NA | -0.31 | type:1.16, stage:-0.07, histology:-0.13, PAM50:-0.14, ER:0.46, PR:-0.05, HER2:0.48, Triple_Negative:-0.09 | |
| 6 | hsa-miR-30c-5p | CAMK2A | 0.29 | 0.7388 | -0.12 | 0.63413 | mirMAP | -0.34 | 0 | NA | -0.35 | type:1.5, stage:-0.14, histology:-0.13, PAM50:-0.17, ER:0.45, PR:0, HER2:0.45, Triple_Negative:0.05 | |
| 7 | hsa-miR-30d-5p | CAMK2A | 0.17 | 0.88286 | -0.12 | 0.63413 | mirMAP | -0.5 | 0 | NA | -0.29 | type:1.39, stage:-0.09, histology:-0.14, PAM50:-0.14, ER:0.42, PR:-0.05, HER2:0.52, Triple_Negative:0 | |
| 8 | hsa-miR-30e-5p | CAMK2A | 0.74 | 0.51197 | -0.12 | 0.63413 | mirMAP | -0.35 | 0 | NA | -0.54 | type:1.59, stage:-0.1, histology:-0.14, PAM50:-0.21, ER:0.38, PR:-0.08, HER2:0.48, Triple_Negative:0.11 | |
| 9 | hsa-miR-361-3p | CAMK2A | 0.35 | 0.60349 | -0.12 | 0.63413 | mirMAP | -0.33 | 4.0E-5 | NA | -0.42 | type:1.3, stage:-0.09, histology:-0.13, PAM50:-0.16, ER:0.38, PR:-0.08, HER2:0.54, Triple_Negative:-0.01 | |
| 10 | hsa-miR-186-5p | CAMK2B | 1.04 | 0.14871 | -1.56 | 0 | miRNAWalker2 validate; miRNATAP | -0.42 | 0 | NA | 0.09 | type:3.24, stage:0.05, histology:0.07, PAM50:0.5, ER:0.75, PR:0.47, HER2:-0.15, Triple_Negative:0.46 | |
| 11 | hsa-miR-2355-5p | CAMK2B | 0.52 | 0.30108 | -1.56 | 0 | mirMAP | -0.53 | 0 | NA | -0.25 | type:2.82, stage:0.06, histology:0.06, PAM50:0.48, ER:0.63, PR:0.36, HER2:-0.11, Triple_Negative:0.44 | |
| 12 | hsa-miR-24-3p | CAMK2B | 0.83 | 0.36962 | -1.56 | 0 | MirTarget | -0.67 | 0 | NA | -0.42 | type:3.05, stage:0.05, histology:0.05, PAM50:0.45, ER:0.64, PR:0.38, HER2:-0.14, Triple_Negative:0.63 | |
| 13 | hsa-miR-362-5p | CAMK2B | 0.82 | 0.01076 | -1.56 | 0 | miRNATAP | -0.37 | 0 | NA | -0.34 | type:2.37, stage:0.09, histology:0.04, PAM50:0.48, ER:0.51, PR:0.38, HER2:-0.17, Triple_Negative:0.47 | |
| 14 | hsa-let-7i-5p | CCND1 | 0.49 | 0.5398 | -1.64 | 0.03536 | miRNATAP | -0.76 | 0 | NA | -0.08 | type:2.76, stage:0.02, histology:0.04, PAM50:0.27, ER:1, PR:-0.14, HER2:0.19, Triple_Negative:-0.12 | |
| 15 | hsa-miR-186-5p | CCND1 | 1.04 | 0.14871 | -1.64 | 0.03536 | mirMAP | -0.49 | 0 | NA | -0.19 | type:2.53, stage:0.02, histology:0.04, PAM50:0.26, ER:0.88, PR:-0.16, HER2:0.16, Triple_Negative:-0.1 | |
| 16 | hsa-miR-29a-3p | CCND1 | 0.46 | 0.68374 | -1.64 | 0.03536 | mirMAP | -0.36 | 0 | NA | -0.03 | type:2.74, stage:0.02, histology:0.04, PAM50:0.27, ER:0.99, PR:-0.13, HER2:0.18, Triple_Negative:-0.13 | |
| 17 | hsa-miR-374a-5p | CCND1 | 0.47 | 0.30955 | -1.64 | 0.03536 | MirTarget | -0.56 | 0 | 27191497 | microRNA 374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway; Furthermore luciferase reporter assays confirmed that miR-374a could directly reduce CCND1; We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues; High miR-374a expression with low level of CCND1 was protective factor in CRC; Together these findings indicate that miR-374a inactivates the PI3K/AKT axis by inhibiting CCND1 suppressing of colon cancer progression | -0.23 | type:2.74, stage:0.02, histology:0.03, PAM50:0.27, ER:1.01, PR:-0.19, HER2:0.22, Triple_Negative:-0.07 |
| 18 | hsa-miR-374b-5p | CCND1 | 0.48 | 0.36577 | -1.64 | 0.03536 | miRNAWalker2 validate; MirTarget | -0.53 | 0 | NA | -0.19 | type:2.66, stage:0.02, histology:0.03, PAM50:0.27, ER:1, PR:-0.17, HER2:0.2, Triple_Negative:-0.1 | |
| 19 | hsa-miR-92a-3p | CCND1 | 1.23 | 0.30313 | -1.64 | 0.03536 | miRNAWalker2 validate | -0.36 | 0 | NA | -0.08 | type:2.79, stage:0.02, histology:0.05, PAM50:0.27, ER:0.98, PR:-0.15, HER2:0.18, Triple_Negative:-0.08 | |
| 20 | hsa-miR-106b-5p | CCND2 | 1.05 | 0.13909 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.32 | 0 | NA | -0.24 | type:-1.44, stage:-0.05, histology:-0.1, PAM50:-0.06, ER:-0.07, PR:0.11, HER2:-0.02, Triple_Negative:0.05 | |
| 21 | hsa-miR-141-3p | CCND2 | 0.52 | 0.54365 | -0.07 | 0.88928 | MirTarget; TargetScan | -0.3 | 0 | NA | -0.18 | type:-1.06, stage:-0.06, histology:-0.08, PAM50:-0.04, ER:-0.05, PR:0.12, HER2:-0.01, Triple_Negative:-0.02 | |
| 22 | hsa-miR-15a-5p | CCND2 | 0.34 | 0.60504 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.38 | 0 | NA | -0.18 | type:-1.47, stage:-0.04, histology:-0.09, PAM50:-0.06, ER:-0.01, PR:0.18, HER2:0, Triple_Negative:-0.01 | |
| 23 | hsa-miR-182-5p | CCND2 | -0.35 | 0.79413 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.33 | 0 | NA | -0.25 | type:-1.22, stage:-0.05, histology:-0.09, PAM50:-0.04, ER:-0.04, PR:0.18, HER2:-0.01, Triple_Negative:-0.17 | |
| 24 | hsa-miR-183-5p | CCND2 | 0.2 | 0.86335 | -0.07 | 0.88928 | miRNATAP | -0.3 | 0 | NA | -0.22 | type:-1.14, stage:-0.04, histology:-0.09, PAM50:-0.05, ER:-0.09, PR:0.14, HER2:0.03, Triple_Negative:-0.12 | |
| 25 | hsa-miR-93-5p | CCND2 | 0.94 | 0.3985 | -0.07 | 0.88928 | miRNATAP | -0.4 | 0 | NA | -0.27 | type:-1.71, stage:-0.02, histology:-0.1, PAM50:-0.08, ER:-0.12, PR:0.12, HER2:-0.02, Triple_Negative:-0.02 | |
| 26 | hsa-miR-96-5p | CCND2 | 0.1 | 0.81662 | -0.07 | 0.88928 | TargetScan; miRNATAP | -0.31 | 0 | NA | -0.25 | type:-1.19, stage:-0.05, histology:-0.08, PAM50:-0.04, ER:-0.12, PR:0.14, HER2:-0.03, Triple_Negative:-0.17 | |
| 27 | hsa-miR-146b-5p | CXXC4 | 0.88 | 0.28494 | -1.31 | 0 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.08 | type:-0.44, stage:-0.15, histology:-0.06, PAM50:0.36, ER:0.52, PR:-0.66, HER2:0.18, Triple_Negative:-0.65 | |
| 28 | hsa-miR-223-3p | CXXC4 | 1.16 | 0.07272 | -1.31 | 0 | MirTarget | -0.34 | 0 | NA | -0.23 | type:-0.89, stage:-0.16, histology:-0.06, PAM50:0.31, ER:0.49, PR:-0.63, HER2:0.06, Triple_Negative:-0.56 | |
| 29 | hsa-miR-532-5p | CXXC4 | 0.84 | 0.32413 | -1.31 | 0 | MirTarget; PITA; miRNATAP | -0.5 | 0 | NA | -0.26 | type:-0.91, stage:-0.15, histology:-0.07, PAM50:0.33, ER:0.4, PR:-0.7, HER2:0.15, Triple_Negative:-0.69 | |
| 30 | hsa-miR-589-5p | CXXC4 | 0.23 | 0.66837 | -1.31 | 0 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.35 | type:-0.45, stage:-0.16, histology:-0.05, PAM50:0.36, ER:0.35, PR:-0.67, HER2:0.29, Triple_Negative:-0.74 | |
| 31 | hsa-miR-660-5p | CXXC4 | 0.79 | 0.10863 | -1.31 | 0 | miRNATAP | -0.56 | 0 | NA | -0.27 | type:-0.88, stage:-0.14, histology:-0.07, PAM50:0.32, ER:0.43, PR:-0.69, HER2:0.13, Triple_Negative:-0.68 | |
| 32 | hsa-miR-181a-5p | DAAM1 | 0.21 | 0.83306 | -0.43 | 0.32793 | mirMAP | -0.32 | 0 | NA | -0.01 | type:-1.49, stage:0.04, histology:-0.01, PAM50:0.04, ER:-0.12, PR:-0.14, HER2:0.2, Triple_Negative:-0.57 | |
| 33 | hsa-miR-141-5p | DAAM2 | 0.15 | 0.85459 | -0.04 | 0.92488 | mirMAP | -0.39 | 0 | NA | -0.29 | type:-0.82, stage:0, histology:0.11, PAM50:-0.11, ER:0.4, PR:-0.19, HER2:-0.11, Triple_Negative:-0.02 | |
| 34 | hsa-miR-182-5p | DAAM2 | -0.35 | 0.79413 | -0.04 | 0.92488 | mirMAP | -0.43 | 0 | NA | -0.24 | type:-1.67, stage:0.02, histology:0.1, PAM50:-0.15, ER:0.32, PR:-0.11, HER2:-0.17, Triple_Negative:-0.26 | |
| 35 | hsa-miR-429 | DAAM2 | 0.45 | 0.43718 | -0.04 | 0.92488 | miRNATAP | -0.34 | 0 | NA | -0.2 | type:-1.2, stage:0.01, histology:0.09, PAM50:-0.17, ER:0.53, PR:-0.22, HER2:-0.19, Triple_Negative:-0.01 | |
| 36 | hsa-miR-455-5p | DKK2 | 1.38 | 0.00151 | -0.76 | 0.0012 | miRanda | -0.33 | 0 | NA | -0.15 | type:-2.42, stage:0.13, histology:-0.01, PAM50:0.07, ER:-0.03, PR:-0.01, HER2:-0.4, Triple_Negative:-0.51 | |
| 37 | hsa-miR-590-5p | DKK2 | 1.4 | 0 | -0.76 | 0.0012 | miRanda | -0.34 | 0 | NA | -0.21 | type:-2.51, stage:0.15, histology:0, PAM50:0.11, ER:-0.23, PR:-0.08, HER2:-0.36, Triple_Negative:-0.57 | |
| 38 | hsa-miR-342-3p | FOSL1 | -0.72 | 0.32809 | 2.26 | 0 | miRanda | -0.4 | 0 | NA | -0.25 | type:-0.72, stage:-0.06, histology:-0.05, PAM50:-0.31, ER:-0.41, PR:-0.07, HER2:-0.34, Triple_Negative:0.94 | |
| 39 | hsa-miR-107 | FZD10 | 0.35 | 0.52382 | -0.3 | 0.16314 | miRanda | -0.4 | 0 | NA | -0.45 | type:0.61, stage:-0.18, histology:0.07, PAM50:-0.05, ER:0.42, PR:-0.11, HER2:-0.2, Triple_Negative:0.04 | |
| 40 | hsa-miR-25-3p | FZD10 | 0.73 | 0.54433 | -0.3 | 0.16314 | miRNATAP | -0.35 | 1.0E-5 | NA | -0.19 | type:-0.06, stage:-0.16, histology:0.07, PAM50:-0.1, ER:0.38, PR:-0.09, HER2:-0.21, Triple_Negative:-0.1 | |
| 41 | hsa-miR-98-5p | FZD10 | 0.61 | 0.24397 | -0.3 | 0.16314 | miRNAWalker2 validate | -0.46 | 0 | NA | -0.3 | type:0.29, stage:-0.15, histology:0.06, PAM50:-0.11, ER:0.43, PR:-0.08, HER2:-0.2, Triple_Negative:-0.03 | |
| 42 | hsa-let-7a-3p | FZD4 | 0.31 | 0.49951 | -0.76 | 0.18617 | mirMAP | -0.41 | 0 | NA | -0.19 | type:-3.99, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.14, PR:-0.05, HER2:0.1, Triple_Negative:-0.89 | |
| 43 | hsa-let-7d-5p | FZD4 | 0.74 | 0.278 | -0.76 | 0.18617 | MirTarget; miRNATAP | -0.38 | 0 | NA | -0.11 | type:-4.26, stage:-0.05, histology:-0.03, PAM50:-0.02, ER:-0.2, PR:-0.03, HER2:0.1, Triple_Negative:-0.94 | |
| 44 | hsa-miR-106b-5p | FZD4 | 1.05 | 0.13909 | -0.76 | 0.18617 | miRNATAP | -0.58 | 0 | NA | -0.2 | type:-4.18, stage:-0.05, histology:-0.03, PAM50:-0.01, ER:-0.26, PR:-0.08, HER2:0.09, Triple_Negative:-0.9 | |
| 45 | hsa-miR-107 | FZD4 | 0.35 | 0.52382 | -0.76 | 0.18617 | miRNATAP | -0.46 | 0 | NA | -0.06 | type:-4.3, stage:-0.05, histology:-0.02, PAM50:-0.01, ER:-0.2, PR:-0.02, HER2:0.11, Triple_Negative:-0.97 | |
| 46 | hsa-miR-130b-3p | FZD4 | 1.17 | 7.0E-5 | -0.76 | 0.18617 | mirMAP | -0.41 | 0 | NA | -0.14 | type:-4.01, stage:-0.05, histology:-0.03, PAM50:0, ER:-0.26, PR:-0.06, HER2:0.15, Triple_Negative:-0.89 | |
| 47 | hsa-miR-141-3p | FZD4 | 0.52 | 0.54365 | -0.76 | 0.18617 | TargetScan | -0.49 | 0 | NA | -0.33 | type:-3.26, stage:-0.07, histology:-0.01, PAM50:0.04, ER:-0.28, PR:-0.14, HER2:0.08, Triple_Negative:-0.91 | |
| 48 | hsa-miR-15a-5p | FZD4 | 0.34 | 0.60504 | -0.76 | 0.18617 | MirTarget | -0.4 | 0 | NA | 0.03 | type:-4.41, stage:-0.04, histology:-0.02, PAM50:-0.01, ER:-0.2, PR:-0.01, HER2:0.11, Triple_Negative:-1.01 | |
| 49 | hsa-miR-15b-5p | FZD4 | 0.69 | 0.30443 | -0.76 | 0.18617 | MirTarget | -0.34 | 0 | NA | -0.09 | type:-4.22, stage:-0.04, histology:-0.02, PAM50:-0.01, ER:-0.21, PR:-0.03, HER2:0.11, Triple_Negative:-0.94 | |
| 50 | hsa-miR-17-3p | FZD4 | 1.47 | 0.04186 | -0.76 | 0.18617 | MirTarget | -0.49 | 0 | NA | -0.37 | type:-3.88, stage:-0.05, histology:-0.03, PAM50:-0.05, ER:-0.26, PR:-0.11, HER2:0.08, Triple_Negative:-0.65 | |
| 51 | hsa-miR-17-5p | FZD4 | 1.81 | 0.01774 | -0.76 | 0.18617 | TargetScan | -0.38 | 0 | NA | -0.21 | type:-4.29, stage:-0.04, histology:-0.03, PAM50:-0.03, ER:-0.33, PR:-0.09, HER2:0.09, Triple_Negative:-0.83 | |
| 52 | hsa-miR-185-5p | FZD4 | 0.41 | 0.43546 | -0.76 | 0.18617 | MirTarget | -0.33 | 0 | NA | 0.12 | type:-4.35, stage:-0.05, histology:-0.02, PAM50:-0.01, ER:-0.17, PR:0, HER2:0.09, Triple_Negative:-1.01 | |
| 53 | hsa-miR-192-5p | FZD4 | 0.47 | 0.53116 | -0.76 | 0.18617 | miRNAWalker2 validate; mirMAP | -0.42 | 0 | NA | -0.18 | type:-4.21, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.25, PR:-0.09, HER2:0.12, Triple_Negative:-1 | |
| 54 | hsa-miR-200b-3p | FZD4 | 0.22 | 0.78639 | -0.76 | 0.18617 | mirMAP | -0.44 | 0 | NA | -0.3 | type:-3.23, stage:-0.08, histology:-0.02, PAM50:0.01, ER:0.06, PR:-0.15, HER2:0.02, Triple_Negative:-0.78 | |
| 55 | hsa-miR-200c-3p | FZD4 | 0.37 | 0.75644 | -0.76 | 0.18617 | mirMAP | -0.54 | 0 | NA | -0.37 | type:-3.68, stage:-0.04, histology:-0.01, PAM50:0.03, ER:-0.31, PR:-0.11, HER2:0.07, Triple_Negative:-0.95 | |
| 56 | hsa-miR-20a-5p | FZD4 | 1.44 | 0.04652 | -0.76 | 0.18617 | miRNATAP | -0.35 | 0 | NA | -0.22 | type:-4.31, stage:-0.04, histology:-0.03, PAM50:-0.04, ER:-0.27, PR:-0.06, HER2:0.09, Triple_Negative:-0.83 | |
| 57 | hsa-miR-21-5p | FZD4 | -0.14 | 0.92885 | -0.76 | 0.18617 | mirMAP | -0.62 | 0 | NA | -0.21 | type:-3.77, stage:-0.05, histology:-0.03, PAM50:-0.01, ER:-0.16, PR:-0.04, HER2:0.2, Triple_Negative:-1 | |
| 58 | hsa-miR-25-3p | FZD4 | 0.73 | 0.54433 | -0.76 | 0.18617 | mirMAP | -0.31 | 0 | NA | -0.17 | type:-4.42, stage:-0.03, histology:-0.03, PAM50:-0.02, ER:-0.23, PR:-0.06, HER2:0.1, Triple_Negative:-0.94 | |
| 59 | hsa-miR-27a-3p | FZD4 | 0.63 | 0.49024 | -0.76 | 0.18617 | miRNATAP | -0.33 | 0 | NA | -0.12 | type:-4.38, stage:-0.04, histology:-0.03, PAM50:-0.03, ER:-0.21, PR:-0.04, HER2:0.11, Triple_Negative:-0.97 | |
| 60 | hsa-miR-3127-5p | FZD4 | 0.15 | 0.56685 | -0.76 | 0.18617 | MirTarget | -0.35 | 0 | NA | -0.22 | type:-4.2, stage:-0.04, histology:-0.03, PAM50:0.04, ER:-0.24, PR:-0.14, HER2:0.15, Triple_Negative:-0.98 | |
| 61 | hsa-miR-32-5p | FZD4 | 0.53 | 0.1955 | -0.76 | 0.18617 | mirMAP | -0.39 | 0 | NA | -0.1 | type:-4.17, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.22, PR:-0.04, HER2:0.11, Triple_Negative:-0.96 | |
| 62 | hsa-miR-324-3p | FZD4 | 0.75 | 0.04368 | -0.76 | 0.18617 | miRNATAP | -0.31 | 0 | NA | -0.16 | type:-4.43, stage:-0.04, histology:-0.03, PAM50:-0.01, ER:-0.26, PR:-0.05, HER2:0.08, Triple_Negative:-0.97 | |
| 63 | hsa-miR-330-5p | FZD4 | 0.56 | 0.19479 | -0.76 | 0.18617 | miRanda; miRNATAP | -0.41 | 0 | NA | -0.28 | type:-3.62, stage:-0.05, histology:-0.03, PAM50:0.01, ER:-0.2, PR:-0.04, HER2:0.17, Triple_Negative:-0.78 | |
| 64 | hsa-miR-429 | FZD4 | 0.45 | 0.43718 | -0.76 | 0.18617 | mirMAP | -0.42 | 0 | NA | -0.25 | type:-3.21, stage:-0.07, histology:-0.02, PAM50:0, ER:0.02, PR:-0.17, HER2:0.06, Triple_Negative:-0.8 | |
| 65 | hsa-miR-454-3p | FZD4 | 0.43 | 0.11673 | -0.76 | 0.18617 | mirMAP | -0.33 | 0 | NA | -0.09 | type:-4.25, stage:-0.05, histology:-0.03, PAM50:0.01, ER:-0.2, PR:-0.09, HER2:0.12, Triple_Negative:-0.98 | |
| 66 | hsa-miR-590-3p | FZD4 | 1.01 | 0 | -0.76 | 0.18617 | miRanda; mirMAP; miRNATAP | -0.41 | 0 | NA | -0.14 | type:-4.19, stage:-0.05, histology:-0.03, PAM50:-0.02, ER:-0.25, PR:-0.05, HER2:0.12, Triple_Negative:-0.95 | |
| 67 | hsa-miR-590-5p | FZD4 | 1.4 | 0 | -0.76 | 0.18617 | mirMAP | -0.33 | 0 | NA | -0.16 | type:-4.54, stage:-0.04, histology:-0.03, PAM50:-0.03, ER:-0.35, PR:-0.07, HER2:0.09, Triple_Negative:-1 | |
| 68 | hsa-miR-92a-3p | FZD4 | 1.23 | 0.30313 | -0.76 | 0.18617 | mirMAP | -0.3 | 0 | NA | -0.33 | type:-4.3, stage:-0.05, histology:-0.02, PAM50:-0.03, ER:-0.3, PR:-0.06, HER2:0.08, Triple_Negative:-0.77 | |
| 69 | hsa-miR-92b-3p | FZD4 | 0.07 | 0.90398 | -0.76 | 0.18617 | mirMAP | -0.35 | 0 | NA | -0.09 | type:-4.17, stage:-0.05, histology:-0.02, PAM50:-0.01, ER:-0.19, PR:-0.02, HER2:0.11, Triple_Negative:-0.97 | |
| 70 | hsa-miR-98-5p | FZD4 | 0.61 | 0.24397 | -0.76 | 0.18617 | MirTarget | -0.53 | 0 | NA | -0.15 | type:-4.23, stage:-0.03, histology:-0.03, PAM50:-0.02, ER:-0.19, PR:-0.03, HER2:0.11, Triple_Negative:-0.93 | |
| 71 | hsa-miR-16-5p | JUN | 0.61 | 0.44106 | -0.11 | 0.88488 | miRNAWalker2 validate | -0.34 | 0 | NA | -0.13 | type:-0.83, stage:-0.08, histology:0.02, PAM50:-0.14, ER:0.13, PR:0.32, HER2:-0.02, Triple_Negative:0.08 | |
| 72 | hsa-miR-590-3p | JUN | 1.01 | 0 | -0.11 | 0.88488 | miRanda | -0.31 | 0 | NA | -0.1 | type:-1.04, stage:-0.07, histology:0.02, PAM50:-0.16, ER:0.07, PR:0.33, HER2:0, Triple_Negative:0.01 | |
| 73 | hsa-miR-130b-3p | MAPK10 | 1.17 | 7.0E-5 | -0.14 | 0.64996 | miRNATAP | -0.31 | 0 | NA | -0.08 | type:-0.86, stage:-0.28, histology:-0.11, PAM50:-0.01, ER:0.12, PR:0.09, HER2:0.44, Triple_Negative:0.21 | |
| 74 | hsa-miR-429 | MAPK10 | 0.45 | 0.43718 | -0.14 | 0.64996 | miRNATAP | -0.37 | 0 | NA | -0.17 | type:-0.26, stage:-0.3, histology:-0.11, PAM50:-0.01, ER:0.31, PR:0, HER2:0.38, Triple_Negative:0.29 | |
| 75 | hsa-miR-590-3p | MAPK10 | 1.01 | 0 | -0.14 | 0.64996 | miRanda; mirMAP | -0.32 | 0 | NA | -0.13 | type:-0.94, stage:-0.27, histology:-0.11, PAM50:-0.02, ER:0.09, PR:0.08, HER2:0.42, Triple_Negative:0.19 | |
| 76 | hsa-miR-361-5p | MAPK8 | 0.3 | 0.67981 | 0.14 | 0.68637 | PITA; miRanda; mirMAP | -0.36 | 0 | NA | -0.13 | type:-0.52, stage:-0.02, histology:-0.01, PAM50:0, ER:0.04, PR:-0.19, HER2:-0.17, Triple_Negative:-0.01 | |
| 77 | hsa-let-7i-5p | MAPK9 | 0.49 | 0.5398 | -0.54 | 0.31405 | miRNATAP | -0.31 | 0 | NA | -0.15 | type:1.22, stage:0.02, histology:0.01, PAM50:0.18, ER:-0.06, PR:0.07, HER2:0.3, Triple_Negative:-0.05 | |
| 78 | hsa-miR-361-5p | MAPK9 | 0.3 | 0.67981 | -0.54 | 0.31405 | miRanda | -0.3 | 0 | NA | -0.09 | type:1.22, stage:0.02, histology:0.01, PAM50:0.19, ER:-0.06, PR:0.07, HER2:0.29, Triple_Negative:-0.07 | |
| 79 | hsa-miR-103a-3p | NFAT5 | -0.07 | 0.95727 | 0.25 | 0.65602 | MirTarget | -0.34 | 0 | NA | -0.02 | type:-0.92, stage:-0.07, histology:0.02, PAM50:-0.03, ER:0.17, PR:-0.25, HER2:-0.13, Triple_Negative:0.12 | |
| 80 | hsa-miR-15a-5p | NFAT5 | 0.34 | 0.60504 | 0.25 | 0.65602 | MirTarget | -0.34 | 0 | NA | -0.1 | type:-0.83, stage:-0.08, histology:0.02, PAM50:-0.02, ER:0.17, PR:-0.26, HER2:-0.13, Triple_Negative:0.15 | |
| 81 | hsa-miR-21-5p | NFAT5 | -0.14 | 0.92885 | 0.25 | 0.65602 | miRNAWalker2 validate; mirMAP | -0.34 | 0 | NA | -0.02 | type:-0.88, stage:-0.08, histology:0.02, PAM50:-0.03, ER:0.18, PR:-0.25, HER2:-0.12, Triple_Negative:0.11 | |
| 82 | hsa-miR-182-5p | NFATC2 | -0.35 | 0.79413 | -0.4 | 0.13655 | mirMAP | -0.32 | 0 | NA | -0.16 | type:-2.11, stage:-0.04, histology:-0.06, PAM50:-0.08, ER:0.28, PR:0.12, HER2:-0.39, Triple_Negative:-0.42 | |
| 83 | hsa-miR-185-5p | NFATC2 | 0.41 | 0.43546 | -0.4 | 0.13655 | MirTarget | -0.48 | 0 | NA | -0.17 | type:-2.44, stage:-0.02, histology:-0.07, PAM50:-0.09, ER:0.25, PR:0.11, HER2:-0.35, Triple_Negative:-0.34 | |
| 84 | hsa-miR-19a-3p | NFATC2 | 1.47 | 0.00036 | -0.4 | 0.13655 | mirMAP | -0.33 | 0 | NA | -0.16 | type:-2.33, stage:-0.02, histology:-0.06, PAM50:-0.1, ER:0.23, PR:0.06, HER2:-0.37, Triple_Negative:-0.27 | |
| 85 | hsa-miR-340-5p | NFATC2 | 0.36 | 0.35065 | -0.4 | 0.13655 | miRNATAP | -0.38 | 0 | NA | -0.06 | type:-1.88, stage:-0.03, histology:-0.06, PAM50:-0.07, ER:0.44, PR:0.06, HER2:-0.32, Triple_Negative:-0.21 | |
| 86 | hsa-miR-3613-5p | NFATC2 | 0.52 | 0.08342 | -0.4 | 0.13655 | mirMAP | -0.34 | 0 | NA | -0.19 | type:-1.51, stage:-0.04, histology:-0.06, PAM50:-0.07, ER:0.42, PR:0.03, HER2:-0.28, Triple_Negative:-0.15 | |
| 87 | hsa-miR-2355-5p | NFATC4 | 0.52 | 0.30108 | -1.31 | 0.01393 | MirTarget | -0.31 | 0 | NA | -0.06 | type:0.44, stage:-0.06, histology:-0.02, PAM50:0.28, ER:0.69, PR:-0.26, HER2:-0.11, Triple_Negative:-0.33 | |
| 88 | hsa-miR-532-5p | NFATC4 | 0.84 | 0.32413 | -1.31 | 0.01393 | mirMAP | -0.35 | 0 | NA | 0 | type:0.52, stage:-0.06, histology:-0.02, PAM50:0.29, ER:0.71, PR:-0.23, HER2:-0.13, Triple_Negative:-0.32 | |
| 89 | hsa-let-7i-5p | NLK | 0.49 | 0.5398 | -0.5 | 0.25036 | miRNATAP | -0.41 | 0 | NA | -0.21 | type:1.13, stage:0.01, histology:0, PAM50:0.13, ER:-0.06, PR:0.02, HER2:0.3, Triple_Negative:-0.11 | |
| 90 | hsa-miR-106b-5p | PLCB1 | 1.05 | 0.13909 | -0.07 | 0.85874 | miRNATAP | -0.35 | 0 | NA | -0.14 | type:-3.44, stage:0.1, histology:-0.04, PAM50:-0.16, ER:-0.42, PR:-0.04, HER2:0.18, Triple_Negative:-0.65 | |
| 91 | hsa-miR-107 | PLCB1 | 0.35 | 0.52382 | -0.07 | 0.85874 | PITA; miRanda; miRNATAP | -0.44 | 0 | NA | -0.16 | type:-3.37, stage:0.1, histology:-0.04, PAM50:-0.14, ER:-0.38, PR:-0.02, HER2:0.2, Triple_Negative:-0.64 | |
| 92 | hsa-miR-93-5p | PLCB1 | 0.94 | 0.3985 | -0.07 | 0.85874 | miRNATAP | -0.38 | 0 | NA | -0.18 | type:-3.61, stage:0.12, histology:-0.04, PAM50:-0.17, ER:-0.46, PR:-0.04, HER2:0.18, Triple_Negative:-0.68 | |
| 93 | hsa-miR-361-5p | PPP2R5E | 0.3 | 0.67981 | -0.11 | 0.80826 | miRanda | -0.36 | 0 | NA | -0.09 | type:0.13, stage:0.04, histology:0.01, PAM50:0, ER:-0.14, PR:0, HER2:0.19, Triple_Negative:-0.18 | |
| 94 | hsa-miR-148b-3p | PRICKLE2 | 0.14 | 0.82572 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.37 | 0 | NA | -0.15 | type:-1.19, stage:-0.08, histology:-0.01, PAM50:0.09, ER:0.2, PR:0.17, HER2:0.22, Triple_Negative:-0.69 | |
| 95 | hsa-miR-15b-3p | PRICKLE2 | 1.34 | 0.00123 | -1.2 | 0.01176 | mirMAP | -0.35 | 0 | NA | -0.15 | type:-1.02, stage:-0.07, histology:-0.02, PAM50:0.08, ER:0.18, PR:0.16, HER2:0.23, Triple_Negative:-0.55 | |
| 96 | hsa-miR-16-2-3p | PRICKLE2 | 1.05 | 0.00013 | -1.2 | 0.01176 | mirMAP | -0.33 | 0 | NA | -0.14 | type:-1.25, stage:-0.07, histology:-0.02, PAM50:0.08, ER:0.19, PR:0.17, HER2:0.19, Triple_Negative:-0.58 | |
| 97 | hsa-miR-181b-5p | PRICKLE2 | 0.52 | 0.50566 | -1.2 | 0.01176 | mirMAP; miRNATAP | -0.32 | 0 | NA | 0 | type:-1.34, stage:-0.07, histology:-0.01, PAM50:0.07, ER:0.23, PR:0.21, HER2:0.21, Triple_Negative:-0.68 | |
| 98 | hsa-miR-186-5p | PRICKLE2 | 1.04 | 0.14871 | -1.2 | 0.01176 | MirTarget | -0.32 | 0 | NA | -0.22 | type:-1.61, stage:-0.06, histology:-0.02, PAM50:0.06, ER:0.1, PR:0.19, HER2:0.18, Triple_Negative:-0.63 | |
| 99 | hsa-miR-18a-5p | PRICKLE2 | 2.3 | 0 | -1.2 | 0.01176 | MirTarget | -0.39 | 0 | NA | -0.19 | type:-1.1, stage:-0.06, histology:-0.02, PAM50:0.04, ER:0.13, PR:0.11, HER2:0.24, Triple_Negative:-0.46 | |
| 100 | hsa-miR-19a-3p | PRICKLE2 | 1.47 | 0.00036 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.19 | type:-1.25, stage:-0.06, histology:-0.02, PAM50:0.06, ER:0.15, PR:0.13, HER2:0.22, Triple_Negative:-0.57 | |
| 101 | hsa-miR-19b-3p | PRICKLE2 | 1.16 | 0.06285 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.19 | type:-1.31, stage:-0.07, histology:-0.01, PAM50:0.06, ER:0.17, PR:0.18, HER2:0.18, Triple_Negative:-0.57 | |
| 102 | hsa-miR-21-5p | PRICKLE2 | -0.14 | 0.92885 | -1.2 | 0.01176 | miRNAWalker2 validate; MirTarget | -0.34 | 0 | NA | -0.01 | type:-1.32, stage:-0.07, histology:-0.01, PAM50:0.07, ER:0.23, PR:0.21, HER2:0.22, Triple_Negative:-0.68 | |
| 103 | hsa-miR-330-5p | PRICKLE2 | 0.56 | 0.19479 | -1.2 | 0.01176 | miRanda; miRNATAP | -0.34 | 0 | NA | -0.29 | type:-0.57, stage:-0.08, histology:-0.02, PAM50:0.1, ER:0.24, PR:0.18, HER2:0.28, Triple_Negative:-0.45 | |
| 104 | hsa-miR-361-5p | PRICKLE2 | 0.3 | 0.67981 | -1.2 | 0.01176 | MirTarget; PITA; miRanda; miRNATAP | -0.42 | 0 | NA | -0.27 | type:-1.45, stage:-0.06, histology:-0.03, PAM50:0.06, ER:0.28, PR:0.18, HER2:0.17, Triple_Negative:-0.61 | |
| 105 | hsa-miR-500a-5p | PRICKLE2 | 1.19 | 0 | -1.2 | 0.01176 | mirMAP | -0.34 | 0 | NA | -0.13 | type:-1.62, stage:-0.06, histology:-0.02, PAM50:0.05, ER:0.18, PR:0.17, HER2:0.19, Triple_Negative:-0.68 | |
| 106 | hsa-miR-576-5p | PRICKLE2 | 1.29 | 5.0E-5 | -1.2 | 0.01176 | mirMAP | -0.32 | 0 | NA | -0.17 | type:-1.41, stage:-0.06, histology:-0.02, PAM50:0.06, ER:0.15, PR:0.16, HER2:0.21, Triple_Negative:-0.61 | |
| 107 | hsa-miR-589-5p | PRICKLE2 | 0.23 | 0.66837 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.41 | 0 | NA | -0.09 | type:-1.33, stage:-0.07, histology:-0.01, PAM50:0.07, ER:0.19, PR:0.21, HER2:0.25, Triple_Negative:-0.69 | |
| 108 | hsa-miR-590-3p | PRICKLE2 | 1.01 | 0 | -1.2 | 0.01176 | MirTarget; PITA; miRanda; mirMAP; miRNATAP | -0.43 | 0 | NA | -0.2 | type:-1.18, stage:-0.07, histology:-0.02, PAM50:0.05, ER:0.14, PR:0.17, HER2:0.23, Triple_Negative:-0.63 | |
| 109 | hsa-miR-590-5p | PRICKLE2 | 1.4 | 0 | -1.2 | 0.01176 | MirTarget; PITA; miRanda | -0.4 | 0 | NA | -0.19 | type:-1.55, stage:-0.06, histology:-0.02, PAM50:0.05, ER:0.05, PR:0.15, HER2:0.19, Triple_Negative:-0.68 | |
| 110 | hsa-miR-93-5p | PRKACB | 0.94 | 0.3985 | -0.26 | 0.62057 | miRNAWalker2 validate | -0.34 | 0 | NA | -0.26 | type:1.5, stage:-0.03, histology:0.04, PAM50:-0.07, ER:0.11, PR:0.08, HER2:0.47, Triple_Negative:0.12 | |
| 111 | hsa-miR-183-5p | PRKCA | 0.2 | 0.86335 | 1.09 | 0.00099 | miRNATAP | -0.38 | 0 | NA | -0.21 | type:-2.18, stage:-0.04, histology:-0.06, PAM50:-0.29, ER:-0.09, PR:-0.25, HER2:-0.12, Triple_Negative:0.17 | |
| 112 | hsa-miR-200b-3p | PRKCA | 0.22 | 0.78639 | 1.09 | 0.00099 | TargetScan | -0.34 | 0 | NA | -0.15 | type:-2.11, stage:-0.06, histology:-0.06, PAM50:-0.3, ER:0.12, PR:-0.27, HER2:-0.19, Triple_Negative:0.31 | |
| 113 | hsa-miR-200c-3p | PRKCA | 0.37 | 0.75644 | 1.09 | 0.00099 | miRNATAP | -0.38 | 0 | NA | -0.2 | type:-2.33, stage:-0.03, histology:-0.06, PAM50:-0.28, ER:-0.07, PR:-0.24, HER2:-0.17, Triple_Negative:0.23 | |
| 114 | hsa-miR-29b-2-5p | PRKCA | -1.15 | 0.02347 | 1.09 | 0.00099 | mirMAP | -0.37 | 0 | NA | -0.27 | type:-2.76, stage:-0.04, histology:-0.05, PAM50:-0.2, ER:-0.02, PR:-0.23, HER2:-0.2, Triple_Negative:0.06 | |
| 115 | hsa-miR-429 | PRKCA | 0.45 | 0.43718 | 1.09 | 0.00099 | miRanda; miRNATAP | -0.3 | 0 | NA | -0.15 | type:-1.93, stage:-0.06, histology:-0.06, PAM50:-0.27, ER:0.09, PR:-0.31, HER2:-0.16, Triple_Negative:0.35 | |
| 116 | hsa-miR-664a-3p | PRKCB | -0.25 | 0.59988 | 0.74 | 0.01718 | mirMAP | -0.31 | 0 | NA | -0.18 | type:-0.33, stage:-0.05, histology:-0.06, PAM50:-0.18, ER:0.12, PR:0.21, HER2:-0.38, Triple_Negative:0.51 | |
| 117 | hsa-miR-29c-3p | PRKX | -0.64 | 0.52285 | 1.92 | 3.0E-5 | mirMAP | -0.39 | 0 | NA | -0.28 | type:-0.81, stage:-0.07, histology:-0.09, PAM50:-0.28, ER:-0.22, PR:-0.2, HER2:-0.22, Triple_Negative:0.74 | |
| 118 | hsa-miR-340-5p | ROCK2 | 0.36 | 0.35065 | 0.38 | 0.43385 | mirMAP | -0.4 | 0 | NA | -0.09 | type:-2.16, stage:0, histology:0, PAM50:-0.09, ER:-0.14, PR:-0.31, HER2:-0.06, Triple_Negative:-0.23 | |
| 119 | hsa-miR-1301-3p | SFRP1 | 1.13 | 0.00036 | 3.81 | 0 | MirTarget | -0.63 | 0 | NA | -0.54 | type:-5.36, stage:-0.13, histology:-0.13, PAM50:-1.1, ER:0.15, PR:-0.44, HER2:-0.96, Triple_Negative:1.68 | |
| 120 | hsa-miR-16-1-3p | SFRP1 | 0.42 | 0.04437 | 3.81 | 0 | MirTarget | -0.71 | 0 | NA | -0.35 | type:-5.14, stage:-0.13, histology:-0.1, PAM50:-1.13, ER:0.51, PR:-0.19, HER2:-1.02, Triple_Negative:1.71 | |
| 121 | hsa-miR-182-5p | SFRP1 | -0.35 | 0.79413 | 3.81 | 0 | mirMAP | -0.97 | 0 | NA | -0.26 | type:-5.71, stage:-0.14, histology:-0.11, PAM50:-1.11, ER:0.42, PR:-0.17, HER2:-1.08, Triple_Negative:1.42 | |
| 122 | hsa-miR-429 | SFRP1 | 0.45 | 0.43718 | 3.81 | 0 | miRNATAP | -0.48 | 0 | NA | -0.13 | type:-5.59, stage:-0.14, histology:-0.12, PAM50:-1.12, ER:0.57, PR:-0.24, HER2:-1.09, Triple_Negative:1.63 | |
| 123 | hsa-miR-484 | SFRP1 | 0.41 | 0.45389 | 3.81 | 0 | MirTarget | -0.74 | 0 | NA | -0.79 | type:-5.75, stage:-0.19, histology:-0.12, PAM50:-1.1, ER:0.39, PR:-0.38, HER2:-1.15, Triple_Negative:1.64 | |
| 124 | hsa-miR-625-5p | SFRP1 | -0.13 | 0.46001 | 3.81 | 0 | MirTarget | -0.63 | 0 | NA | -0.2 | type:-5.05, stage:-0.1, histology:-0.11, PAM50:-1.1, ER:0.61, PR:-0.14, HER2:-0.94, Triple_Negative:1.75 | |
| 125 | hsa-miR-7-1-3p | SFRP1 | -0.14 | 0.72688 | 3.81 | 0 | MirTarget; mirMAP | -0.63 | 0 | NA | -0.31 | type:-6.3, stage:-0.1, histology:-0.11, PAM50:-1.1, ER:0.41, PR:-0.25, HER2:-1.13, Triple_Negative:1.41 | |
| 126 | hsa-miR-96-5p | SFRP1 | 0.1 | 0.81662 | 3.81 | 0 | mirMAP | -0.84 | 0 | NA | -0.36 | type:-5.51, stage:-0.13, histology:-0.1, PAM50:-1.1, ER:0.29, PR:-0.23, HER2:-1.11, Triple_Negative:1.38 | |
| 127 | hsa-let-7a-3p | SFRP2 | 0.31 | 0.49951 | -1.02 | 0.19917 | miRNATAP | -0.33 | 0 | NA | -0.3 | type:1.24, stage:-0.03, histology:-0.08, PAM50:0.01, ER:0.45, PR:0.05, HER2:0.47, Triple_Negative:-0.43 | |
| 128 | hsa-miR-590-3p | SFRP2 | 1.01 | 0 | -1.02 | 0.19917 | miRanda | -0.31 | 0 | NA | -0.31 | type:1.16, stage:-0.03, histology:-0.09, PAM50:-0.02, ER:0.26, PR:0.02, HER2:0.52, Triple_Negative:-0.46 | |
| 129 | hsa-miR-429 | SFRP4 | 0.45 | 0.43718 | -0.94 | 0.12967 | miRanda | -0.31 | 0 | NA | -0.24 | type:0.38, stage:-0.11, histology:-0.03, PAM50:-0.04, ER:0.51, PR:0.14, HER2:0.07, Triple_Negative:-0.37 | |
| 130 | hsa-miR-532-5p | SFRP4 | 0.84 | 0.32413 | -0.94 | 0.12967 | MirTarget | -0.35 | 0 | NA | 0.08 | type:-0.54, stage:-0.09, histology:-0.02, PAM50:-0.02, ER:0.31, PR:0.29, HER2:0.13, Triple_Negative:-0.55 | |
| 131 | hsa-miR-141-3p | SOX17 | 0.52 | 0.54365 | -0.56 | 0.03082 | TargetScan | -0.43 | 0 | 22921431 | Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer; MicroRNA 141 was also found to down-regulate SOX17 expression and activate the WNT signal pathway | -0.27 | type:-1.81, stage:-0.08, histology:0.04, PAM50:0.02, ER:0.02, PR:-0.01, HER2:-0.05, Triple_Negative:-0.32 |
| 132 | hsa-miR-330-5p | SOX17 | 0.56 | 0.19479 | -0.56 | 0.03082 | miRanda | -0.46 | 0 | NA | -0.18 | type:-2.24, stage:-0.06, histology:0.02, PAM50:-0.01, ER:0.09, PR:0.08, HER2:0.01, Triple_Negative:-0.26 | |
| 133 | hsa-miR-590-3p | SOX17 | 1.01 | 0 | -0.56 | 0.03082 | miRanda; miRNATAP | -0.44 | 0 | NA | -0.09 | type:-2.62, stage:-0.05, histology:0.02, PAM50:-0.02, ER:0.05, PR:0.07, HER2:-0.02, Triple_Negative:-0.37 | |
| 134 | hsa-miR-590-5p | SOX17 | 1.4 | 0 | -0.56 | 0.03082 | miRanda | -0.39 | 0 | NA | -0.1 | type:-2.84, stage:-0.05, histology:0.02, PAM50:-0.03, ER:-0.02, PR:0.06, HER2:-0.04, Triple_Negative:-0.39 | |
| 135 | hsa-miR-148b-3p | TCF7L2 | 0.14 | 0.82572 | 0.81 | 0.09031 | miRNAWalker2 validate | -0.36 | 0 | NA | -0.2 | type:-1.45, stage:-0.06, histology:-0.05, PAM50:-0.28, ER:0.04, PR:-0.03, HER2:-0.02, Triple_Negative:0.23 | |
| 136 | hsa-miR-26a-5p | VANGL1 | -0.05 | 0.95817 | 0.09 | 0.85194 | mirMAP | -0.38 | 0 | NA | -0.25 | type:1.19, stage:0.01, histology:0.01, PAM50:0.04, ER:-0.26, PR:0.09, HER2:0.17, Triple_Negative:0.03 | |
| 137 | hsa-miR-107 | WIF1 | 0.35 | 0.52382 | 2.05 | 3.0E-5 | miRanda | -0.81 | 1.0E-5 | NA | -0.81 | type:-3.39, stage:-0.37, histology:-0.15, PAM50:-0.45, ER:0.11, PR:0.07, HER2:-0.17, Triple_Negative:1.68 | |
| 138 | hsa-miR-330-5p | WIF1 | 0.56 | 0.19479 | 2.05 | 3.0E-5 | miRanda | -0.66 | 0 | NA | -0.34 | type:-3.56, stage:-0.36, histology:-0.14, PAM50:-0.49, ER:0.1, PR:0.15, HER2:-0.11, Triple_Negative:1.58 | |
| 139 | hsa-miR-342-3p | WIF1 | -0.72 | 0.32809 | 2.05 | 3.0E-5 | miRanda | -0.9 | 0 | NA | -0.04 | type:-4.35, stage:-0.35, histology:-0.13, PAM50:-0.51, ER:0.11, PR:0.19, HER2:-0.19, Triple_Negative:1.33 | |
| 140 | hsa-miR-429 | WIF1 | 0.45 | 0.43718 | 2.05 | 3.0E-5 | miRanda | -0.58 | 0 | NA | -0.1 | type:-4.24, stage:-0.35, histology:-0.13, PAM50:-0.56, ER:0.23, PR:0.15, HER2:-0.23, Triple_Negative:1.36 | |
| 141 | hsa-miR-590-3p | WIF1 | 1.01 | 0 | 2.05 | 3.0E-5 | PITA; miRanda; mirMAP | -0.64 | 0 | NA | -0.44 | type:-3.84, stage:-0.32, histology:-0.14, PAM50:-0.54, ER:-0.07, PR:0.06, HER2:-0.11, Triple_Negative:1.5 | |
| 142 | hsa-miR-664a-3p | WNT10A | -0.25 | 0.59988 | 2.09 | 0 | mirMAP | -0.42 | 0 | NA | -0.23 | type:-1.33, stage:0.07, histology:-0.16, PAM50:-0.41, ER:-0.25, PR:0.09, HER2:-0.37, Triple_Negative:0.87 | |
| 143 | hsa-miR-148b-3p | WNT10B | 0.14 | 0.82572 | 0.48 | 0.02831 | MirTarget | -0.33 | 0 | NA | 0.09 | type:-1.34, stage:-0.06, histology:-0.09, PAM50:-0.05, ER:0.41, PR:-0.25, HER2:0.01, Triple_Negative:0.46 | |
| 144 | hsa-miR-374a-5p | WNT3 | 0.47 | 0.30955 | -0.24 | 0.21582 | MirTarget | -0.45 | 0 | NA | -0.31 | type:2.78, stage:-0.04, histology:0.03, PAM50:0.32, ER:0.64, PR:-0.13, HER2:-0.56, Triple_Negative:0.95 | |
| 145 | hsa-miR-374b-5p | WNT3 | 0.48 | 0.36577 | -0.24 | 0.21582 | MirTarget | -0.34 | 0 | NA | -0.12 | type:2.75, stage:-0.03, histology:0.04, PAM50:0.32, ER:0.63, PR:-0.08, HER2:-0.59, Triple_Negative:0.89 | |
| 146 | hsa-miR-16-2-3p | WNT5A | 1.05 | 0.00013 | -0.49 | 0.23864 | MirTarget; mirMAP | -0.34 | 0 | NA | -0.28 | type:2.26, stage:-0.2, histology:-0.12, PAM50:-0.07, ER:0.06, PR:0.73, HER2:0.4, Triple_Negative:0.36 | |
| 147 | hsa-miR-16-5p | WNT5A | 0.61 | 0.44106 | -0.49 | 0.23864 | miRNAWalker2 validate | -0.44 | 0 | NA | -0.48 | type:2.47, stage:-0.21, histology:-0.1, PAM50:-0.03, ER:-0.02, PR:0.72, HER2:0.36, Triple_Negative:0.35 | |
| 148 | hsa-miR-186-5p | WNT5A | 1.04 | 0.14871 | -0.49 | 0.23864 | miRNAWalker2 validate; mirMAP; miRNATAP | -0.3 | 0 | NA | -0.4 | type:1.49, stage:-0.2, histology:-0.12, PAM50:-0.09, ER:-0.14, PR:0.74, HER2:0.36, Triple_Negative:0.24 | |
| 149 | hsa-miR-30d-3p | WNT5A | 0.27 | 0.27013 | -0.49 | 0.23864 | mirMAP | -0.33 | 0 | NA | -0.2 | type:1.52, stage:-0.2, histology:-0.12, PAM50:-0.07, ER:-0.01, PR:0.78, HER2:0.33, Triple_Negative:0.06 | |
| 150 | hsa-miR-30d-5p | WNT5A | 0.17 | 0.88286 | -0.49 | 0.23864 | mirMAP | -0.4 | 0 | NA | -0.22 | type:1.88, stage:-0.21, histology:-0.12, PAM50:-0.05, ER:0.1, PR:0.76, HER2:0.37, Triple_Negative:0.19 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | WNT SIGNALING PATHWAY | 25 | 351 | 1.053e-33 | 4.9e-30 |
| 2 | REGULATION OF WNT SIGNALING PATHWAY | 16 | 310 | 8.728e-19 | 1.354e-15 |
| 3 | CANONICAL WNT SIGNALING PATHWAY | 12 | 95 | 6.32e-19 | 1.354e-15 |
| 4 | NON CANONICAL WNT SIGNALING PATHWAY | 13 | 140 | 1.177e-18 | 1.369e-15 |
| 5 | NEGATIVE REGULATION OF WNT SIGNALING PATHWAY | 14 | 197 | 2.106e-18 | 1.96e-15 |
| 6 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 25 | 1672 | 6.024e-17 | 4.672e-14 |
| 7 | REGULATION OF CELL DIFFERENTIATION | 23 | 1492 | 1.127e-15 | 7.494e-13 |
| 8 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 18 | 823 | 1.33e-14 | 7.738e-12 |
| 9 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 20 | 1142 | 1.779e-14 | 9.2e-12 |
| 10 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 19 | 1021 | 3.511e-14 | 1.634e-11 |
| 11 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 20 | 1381 | 6.282e-13 | 2.657e-10 |
| 12 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 22 | 1848 | 1.296e-12 | 5.025e-10 |
| 13 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 22 | 1929 | 3.075e-12 | 1.101e-09 |
| 14 | POSITIVE REGULATION OF GENE EXPRESSION | 21 | 1733 | 3.97e-12 | 1.319e-09 |
| 15 | POSITIVE REGULATION OF CELL COMMUNICATION | 20 | 1532 | 4.283e-12 | 1.329e-09 |
| 16 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 21 | 1791 | 7.469e-12 | 2.11e-09 |
| 17 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 12 | 365 | 7.708e-12 | 2.11e-09 |
| 18 | CELL FATE COMMITMENT | 10 | 227 | 3.116e-11 | 8.055e-09 |
| 19 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 15 | 799 | 3.335e-11 | 8.166e-09 |
| 20 | NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 9 | 162 | 4.257e-11 | 9.904e-09 |
| 21 | REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 10 | 236 | 4.572e-11 | 1.013e-08 |
| 22 | CELLULAR RESPONSE TO RETINOIC ACID | 7 | 65 | 6.773e-11 | 1.432e-08 |
| 23 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 18 | 1395 | 9.672e-11 | 1.957e-08 |
| 24 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 6 | 39 | 1.831e-10 | 3.408e-08 |
| 25 | POSITIVE REGULATION OF CELL DEATH | 13 | 605 | 1.782e-10 | 3.408e-08 |
| 26 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 18 | 1492 | 2.904e-10 | 5.197e-08 |
| 27 | REGULATION OF CELL CYCLE | 15 | 949 | 3.693e-10 | 6.364e-08 |
| 28 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 16 | 1152 | 5.318e-10 | 8.837e-08 |
| 29 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 17 | 1360 | 6.419e-10 | 1.03e-07 |
| 30 | PATTERN SPECIFICATION PROCESS | 11 | 418 | 6.972e-10 | 1.081e-07 |
| 31 | POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 8 | 152 | 8.769e-10 | 1.275e-07 |
| 32 | NEGATIVE REGULATION OF CELL COMMUNICATION | 16 | 1192 | 8.751e-10 | 1.275e-07 |
| 33 | REGULATION OF ORGAN MORPHOGENESIS | 9 | 242 | 1.509e-09 | 2.128e-07 |
| 34 | CELLULAR RESPONSE TO LIPID | 11 | 457 | 1.778e-09 | 2.364e-07 |
| 35 | RESPONSE TO LIPID | 14 | 888 | 1.73e-09 | 2.364e-07 |
| 36 | RESPONSE TO RETINOIC ACID | 7 | 107 | 2.378e-09 | 3.074e-07 |
| 37 | CELLULAR RESPONSE TO ACID CHEMICAL | 8 | 175 | 2.68e-09 | 3.282e-07 |
| 38 | REGULATION OF PROTEIN MODIFICATION PROCESS | 18 | 1710 | 2.624e-09 | 3.282e-07 |
| 39 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY | 7 | 110 | 2.889e-09 | 3.447e-07 |
| 40 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 17 | 1518 | 3.444e-09 | 4.006e-07 |
| 41 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 17 | 1618 | 9.026e-09 | 1.024e-06 |
| 42 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 14 | 1036 | 1.242e-08 | 1.344e-06 |
| 43 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 14 | 1036 | 1.242e-08 | 1.344e-06 |
| 44 | REGULATION OF CELL DEATH | 16 | 1472 | 1.815e-08 | 1.919e-06 |
| 45 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 9 | 337 | 2.69e-08 | 2.782e-06 |
| 46 | VASCULATURE DEVELOPMENT | 10 | 469 | 3.433e-08 | 3.472e-06 |
| 47 | EPITHELIUM DEVELOPMENT | 13 | 945 | 3.836e-08 | 3.642e-06 |
| 48 | PROTEIN PHOSPHORYLATION | 13 | 944 | 3.788e-08 | 3.642e-06 |
| 49 | REGULATION OF JNK CASCADE | 7 | 159 | 3.754e-08 | 3.642e-06 |
| 50 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 14 | 1135 | 3.924e-08 | 3.652e-06 |
| 51 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 17 | 1805 | 4.605e-08 | 4.201e-06 |
| 52 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 12 | 788 | 4.79e-08 | 4.205e-06 |
| 53 | CIRCULATORY SYSTEM DEVELOPMENT | 12 | 788 | 4.79e-08 | 4.205e-06 |
| 54 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 12 | 801 | 5.73e-08 | 4.937e-06 |
| 55 | NEUROGENESIS | 15 | 1402 | 7.3e-08 | 6.175e-06 |
| 56 | DORSAL VENTRAL AXIS SPECIFICATION | 4 | 20 | 7.941e-08 | 6.598e-06 |
| 57 | RESPONSE TO ABIOTIC STIMULUS | 13 | 1024 | 9.814e-08 | 8.011e-06 |
| 58 | TISSUE MORPHOGENESIS | 10 | 533 | 1.135e-07 | 9.108e-06 |
| 59 | MORPHOGENESIS OF AN EPITHELIUM | 9 | 400 | 1.164e-07 | 9.18e-06 |
| 60 | REGULATION OF CELLULAR RESPONSE TO STRESS | 11 | 691 | 1.246e-07 | 9.664e-06 |
| 61 | REGULATION OF EMBRYONIC DEVELOPMENT | 6 | 114 | 1.333e-07 | 1.017e-05 |
| 62 | NEURON DIFFERENTIATION | 12 | 874 | 1.48e-07 | 1.111e-05 |
| 63 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 7 | 197 | 1.629e-07 | 1.203e-05 |
| 64 | POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 6 | 119 | 1.721e-07 | 1.232e-05 |
| 65 | REGULATION OF CELL PROLIFERATION | 15 | 1496 | 1.711e-07 | 1.232e-05 |
| 66 | REGIONALIZATION | 8 | 311 | 2.329e-07 | 1.642e-05 |
| 67 | NEGATIVE REGULATION OF EMBRYONIC DEVELOPMENT | 4 | 26 | 2.428e-07 | 1.686e-05 |
| 68 | REGULATION OF HYDROLASE ACTIVITY | 14 | 1327 | 2.719e-07 | 1.86e-05 |
| 69 | RESPONSE TO ACID CHEMICAL | 8 | 319 | 2.826e-07 | 1.905e-05 |
| 70 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 12 | 957 | 3.929e-07 | 2.539e-05 |
| 71 | POSITIVE REGULATION OF CELL CYCLE | 8 | 332 | 3.827e-07 | 2.539e-05 |
| 72 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 10 | 609 | 3.888e-07 | 2.539e-05 |
| 73 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 9 | 470 | 4.534e-07 | 2.89e-05 |
| 74 | PEPTIDYL SERINE MODIFICATION | 6 | 148 | 6.246e-07 | 3.928e-05 |
| 75 | NEGATIVE REGULATION OF CELL PROLIFERATION | 10 | 643 | 6.389e-07 | 3.963e-05 |
| 76 | REGULATION OF JUN KINASE ACTIVITY | 5 | 81 | 7.272e-07 | 4.452e-05 |
| 77 | BLOOD VESSEL MORPHOGENESIS | 8 | 364 | 7.666e-07 | 4.633e-05 |
| 78 | RESPONSE TO ENDOGENOUS STIMULUS | 14 | 1450 | 7.978e-07 | 4.699e-05 |
| 79 | PHOSPHORYLATION | 13 | 1228 | 7.911e-07 | 4.699e-05 |
| 80 | REGULATION OF MAPK CASCADE | 10 | 660 | 8.101e-07 | 4.712e-05 |
| 81 | ORGAN MORPHOGENESIS | 11 | 841 | 8.813e-07 | 5.062e-05 |
| 82 | AXIS SPECIFICATION | 5 | 90 | 1.23e-06 | 6.981e-05 |
| 83 | TISSUE DEVELOPMENT | 14 | 1518 | 1.383e-06 | 7.752e-05 |
| 84 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 12 | 1079 | 1.402e-06 | 7.766e-05 |
| 85 | EMBRYO DEVELOPMENT | 11 | 894 | 1.603e-06 | 8.777e-05 |
| 86 | REGULATION OF CELL MORPHOGENESIS | 9 | 552 | 1.723e-06 | 9.322e-05 |
| 87 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 9 | 554 | 1.775e-06 | 9.493e-05 |
| 88 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 11 | 905 | 1.806e-06 | 9.55e-05 |
| 89 | REGULATION OF OSSIFICATION | 6 | 178 | 1.837e-06 | 9.602e-05 |
| 90 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 7 | 285 | 1.951e-06 | 0.0001008 |
| 91 | RESPONSE TO RADIATION | 8 | 413 | 1.972e-06 | 0.0001008 |
| 92 | INTRACELLULAR SIGNAL TRANSDUCTION | 14 | 1572 | 2.097e-06 | 0.000106 |
| 93 | HEMATOPOIETIC STEM CELL PROLIFERATION | 3 | 13 | 2.427e-06 | 0.0001214 |
| 94 | PEPTIDYL THREONINE MODIFICATION | 4 | 46 | 2.571e-06 | 0.0001273 |
| 95 | RHYTHMIC PROCESS | 7 | 298 | 2.622e-06 | 0.0001284 |
| 96 | RESPONSE TO DRUG | 8 | 431 | 2.706e-06 | 0.0001312 |
| 97 | REGULATION OF FAT CELL DIFFERENTIATION | 5 | 106 | 2.768e-06 | 0.0001328 |
| 98 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 3 | 14 | 3.084e-06 | 0.0001421 |
| 99 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 6 | 194 | 3.024e-06 | 0.0001421 |
| 100 | DIGESTIVE TRACT MORPHOGENESIS | 4 | 48 | 3.056e-06 | 0.0001421 |
| 101 | CONVERGENT EXTENSION | 3 | 14 | 3.084e-06 | 0.0001421 |
| 102 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 10 | 771 | 3.282e-06 | 0.0001497 |
| 103 | REGULATION OF KINASE ACTIVITY | 10 | 776 | 3.476e-06 | 0.000157 |
| 104 | REGULATION OF OSTEOBLAST DIFFERENTIATION | 5 | 112 | 3.63e-06 | 0.0001624 |
| 105 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 14 | 1656 | 3.875e-06 | 0.0001717 |
| 106 | CELL DEVELOPMENT | 13 | 1426 | 4.207e-06 | 0.0001847 |
| 107 | NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 5 | 117 | 4.499e-06 | 0.000192 |
| 108 | TUBE MORPHOGENESIS | 7 | 323 | 4.459e-06 | 0.000192 |
| 109 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 7 | 323 | 4.459e-06 | 0.000192 |
| 110 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 4 | 53 | 4.565e-06 | 0.0001931 |
| 111 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 5 | 122 | 5.523e-06 | 0.0002315 |
| 112 | OUTFLOW TRACT MORPHOGENESIS | 4 | 56 | 5.7e-06 | 0.0002368 |
| 113 | REGULATION OF RESPONSE TO STRESS | 13 | 1468 | 5.788e-06 | 0.0002383 |
| 114 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 6.721e-06 | 0.0002743 |
| 115 | STEM CELL PROLIFERATION | 4 | 60 | 7.521e-06 | 0.0003043 |
| 116 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 6 | 228 | 7.65e-06 | 0.0003069 |
| 117 | REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 3 | 19 | 8.151e-06 | 0.0003242 |
| 118 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 13 | 1517 | 8.284e-06 | 0.0003266 |
| 119 | SOMITOGENESIS | 4 | 62 | 8.578e-06 | 0.0003354 |
| 120 | REGULATION OF VASCULATURE DEVELOPMENT | 6 | 233 | 8.659e-06 | 0.0003357 |
| 121 | MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 5 | 134 | 8.732e-06 | 0.0003358 |
| 122 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 5 | 142 | 1.158e-05 | 0.0004415 |
| 123 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 4 | 67 | 1.17e-05 | 0.0004425 |
| 124 | RESPONSE TO HORMONE | 10 | 893 | 1.198e-05 | 0.0004494 |
| 125 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 5 | 144 | 1.239e-05 | 0.0004611 |
| 126 | CARTILAGE DEVELOPMENT | 5 | 147 | 1.369e-05 | 0.0005055 |
| 127 | EMBRYONIC MORPHOGENESIS | 8 | 539 | 1.391e-05 | 0.0005055 |
| 128 | RESPONSE TO CYTOKINE | 9 | 714 | 1.387e-05 | 0.0005055 |
| 129 | NEURAL TUBE DEVELOPMENT | 5 | 149 | 1.462e-05 | 0.0005272 |
| 130 | TUBE DEVELOPMENT | 8 | 552 | 1.652e-05 | 0.0005867 |
| 131 | GLAND DEVELOPMENT | 7 | 395 | 1.652e-05 | 0.0005867 |
| 132 | POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 3 | 24 | 1.69e-05 | 0.0005958 |
| 133 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 5 | 154 | 1.714e-05 | 0.0005981 |
| 134 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 6 | 263 | 1.722e-05 | 0.0005981 |
| 135 | REGULATION OF CELL CYCLE PROCESS | 8 | 558 | 1.785e-05 | 0.0006153 |
| 136 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 7 | 404 | 1.91e-05 | 0.0006533 |
| 137 | REGULATION OF TRANSFERASE ACTIVITY | 10 | 946 | 1.974e-05 | 0.0006657 |
| 138 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 7 | 406 | 1.971e-05 | 0.0006657 |
| 139 | REPRODUCTIVE SYSTEM DEVELOPMENT | 7 | 408 | 2.034e-05 | 0.000681 |
| 140 | SOMITE DEVELOPMENT | 4 | 78 | 2.141e-05 | 0.0007115 |
| 141 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 5 | 162 | 2.188e-05 | 0.0007222 |
| 142 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 9 | 767 | 2.446e-05 | 0.000796 |
| 143 | AXIS ELONGATION | 3 | 27 | 2.432e-05 | 0.000796 |
| 144 | JNK CASCADE | 4 | 82 | 2.609e-05 | 0.000843 |
| 145 | NEGATIVE REGULATION OF CELL GROWTH | 5 | 170 | 2.759e-05 | 0.0008792 |
| 146 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 10 | 983 | 2.746e-05 | 0.0008792 |
| 147 | NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH | 4 | 84 | 2.869e-05 | 0.0009021 |
| 148 | POSITIVE REGULATION OF OSSIFICATION | 4 | 84 | 2.869e-05 | 0.0009021 |
| 149 | REGULATION OF DEVELOPMENTAL GROWTH | 6 | 289 | 2.928e-05 | 0.0009082 |
| 150 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 289 | 2.928e-05 | 0.0009082 |
| 151 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 14 | 1977 | 2.972e-05 | 0.0009158 |
| 152 | ANGIOGENESIS | 6 | 293 | 3.162e-05 | 0.000968 |
| 153 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 10 | 1004 | 3.29e-05 | 0.001001 |
| 154 | RESPONSE TO X RAY | 3 | 30 | 3.361e-05 | 0.001015 |
| 155 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 10 | 1008 | 3.404e-05 | 0.001022 |
| 156 | SEGMENTATION | 4 | 89 | 3.604e-05 | 0.001075 |
| 157 | REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 3 | 31 | 3.715e-05 | 0.001101 |
| 158 | NEGATIVE REGULATION OF GENE EXPRESSION | 12 | 1493 | 3.847e-05 | 0.001126 |
| 159 | RESPONSE TO KETONE | 5 | 182 | 3.824e-05 | 0.001126 |
| 160 | POSITIVE REGULATION OF CELL PROLIFERATION | 9 | 814 | 3.901e-05 | 0.001134 |
| 161 | DORSAL VENTRAL PATTERN FORMATION | 4 | 91 | 3.933e-05 | 0.001137 |
| 162 | SKELETAL SYSTEM DEVELOPMENT | 7 | 455 | 4.08e-05 | 0.001172 |
| 163 | NEURAL TUBE FORMATION | 4 | 94 | 4.467e-05 | 0.001275 |
| 164 | STEM CELL DIFFERENTIATION | 5 | 190 | 4.695e-05 | 0.001324 |
| 165 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 13 | 1784 | 4.679e-05 | 0.001324 |
| 166 | BRAIN MORPHOGENESIS | 3 | 34 | 4.925e-05 | 0.00138 |
| 167 | POSITIVE REGULATION OF MAPK CASCADE | 7 | 470 | 5.01e-05 | 0.001396 |
| 168 | REGULATION OF MAP KINASE ACTIVITY | 6 | 319 | 5.08e-05 | 0.001407 |
| 169 | CONNECTIVE TISSUE DEVELOPMENT | 5 | 194 | 5.184e-05 | 0.001427 |
| 170 | REGULATION OF TRANSPORT | 13 | 1804 | 5.257e-05 | 0.001439 |
| 171 | RESPONSE TO GROWTH FACTOR | 7 | 475 | 5.357e-05 | 0.001458 |
| 172 | RESPONSE TO INORGANIC SUBSTANCE | 7 | 479 | 5.648e-05 | 0.001528 |
| 173 | POSITIVE REGULATION OF KINASE ACTIVITY | 7 | 482 | 5.874e-05 | 0.00158 |
| 174 | RESPONSE TO NITROGEN COMPOUND | 9 | 859 | 5.925e-05 | 0.001585 |
| 175 | CELL CYCLE | 11 | 1316 | 6.163e-05 | 0.001611 |
| 176 | CELLULAR RESPONSE TO STRESS | 12 | 1565 | 6.104e-05 | 0.001611 |
| 177 | SKELETAL SYSTEM MORPHOGENESIS | 5 | 201 | 6.133e-05 | 0.001611 |
| 178 | CELL CYCLE PROCESS | 10 | 1081 | 6.154e-05 | 0.001611 |
| 179 | REGULATION OF CIRCADIAN RHYTHM | 4 | 103 | 6.388e-05 | 0.001642 |
| 180 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 4 | 103 | 6.388e-05 | 0.001642 |
| 181 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 103 | 6.388e-05 | 0.001642 |
| 182 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 4 | 104 | 6.634e-05 | 0.001696 |
| 183 | CELL PROLIFERATION | 8 | 672 | 6.688e-05 | 0.001701 |
| 184 | SENSORY ORGAN DEVELOPMENT | 7 | 493 | 6.77e-05 | 0.001703 |
| 185 | REGULATION OF GTPASE ACTIVITY | 8 | 673 | 6.758e-05 | 0.001703 |
| 186 | FC RECEPTOR SIGNALING PATHWAY | 5 | 206 | 6.89e-05 | 0.001715 |
| 187 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 9 | 876 | 6.893e-05 | 0.001715 |
| 188 | HEART MORPHOGENESIS | 5 | 212 | 7.892e-05 | 0.001953 |
| 189 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 8.06e-05 | 0.001984 |
| 190 | DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 5 | 216 | 8.619e-05 | 0.002111 |
| 191 | REGULATION OF STEM CELL DIFFERENTIATION | 4 | 113 | 9.163e-05 | 0.002232 |
| 192 | NEGATIVE REGULATION OF BMP SIGNALING PATHWAY | 3 | 42 | 9.338e-05 | 0.002263 |
| 193 | NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 4 | 115 | 9.809e-05 | 0.00234 |
| 194 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 9 | 917 | 9.792e-05 | 0.00234 |
| 195 | RESPONSE TO INTERLEUKIN 1 | 4 | 115 | 9.809e-05 | 0.00234 |
| 196 | RESPONSE TO ALCOHOL | 6 | 362 | 0.0001021 | 0.002423 |
| 197 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 6 | 363 | 0.0001036 | 0.002448 |
| 198 | MAMMARY GLAND DEVELOPMENT | 4 | 117 | 0.0001049 | 0.002464 |
| 199 | REGULATION OF IMMUNE SYSTEM PROCESS | 11 | 1403 | 0.0001098 | 0.002566 |
| 200 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 5 | 229 | 0.0001135 | 0.00264 |
| 201 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 4 | 123 | 0.0001273 | 0.002946 |
| 202 | NEGATIVE REGULATION OF GROWTH | 5 | 236 | 0.0001306 | 0.003009 |
| 203 | POSITIVE REGULATION OF GROWTH | 5 | 238 | 0.0001359 | 0.003115 |
| 204 | RESPONSE TO UV | 4 | 126 | 0.0001397 | 0.003185 |
| 205 | REGULATION OF REPRODUCTIVE PROCESS | 4 | 129 | 0.0001529 | 0.003454 |
| 206 | TUBE FORMATION | 4 | 129 | 0.0001529 | 0.003454 |
| 207 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 5 | 247 | 0.0001616 | 0.003633 |
| 208 | MITOTIC CELL CYCLE | 8 | 766 | 0.0001658 | 0.003709 |
| 209 | POSITIVE REGULATION OF FAT CELL DIFFERENTIATION | 3 | 51 | 0.0001672 | 0.003722 |
| 210 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 4 | 133 | 0.000172 | 0.003811 |
| 211 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 0.0001821 | 0.004016 |
| 212 | CELL DEATH | 9 | 1001 | 0.0001902 | 0.004174 |
| 213 | CELLULAR RESPONSE TO RADIATION | 4 | 137 | 0.0001927 | 0.00421 |
| 214 | NEGATIVE REGULATION OF LOCOMOTION | 5 | 263 | 0.0002163 | 0.004704 |
| 215 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 5 | 264 | 0.0002202 | 0.004765 |
| 216 | SEX DIFFERENTIATION | 5 | 266 | 0.000228 | 0.004912 |
| 217 | BONE TRABECULA MORPHOGENESIS | 2 | 11 | 0.000234 | 0.004948 |
| 218 | POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 2 | 11 | 0.000234 | 0.004948 |
| 219 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 7 | 602 | 0.0002333 | 0.004948 |
| 220 | APOPTOTIC MITOCHONDRIAL CHANGES | 3 | 57 | 0.0002328 | 0.004948 |
| 221 | REGULATION OF CELLULAR LOCALIZATION | 10 | 1277 | 0.0002438 | 0.005132 |
| 222 | REGULATION OF CELL DIVISION | 5 | 272 | 0.0002528 | 0.005298 |
| 223 | DIGESTIVE SYSTEM DEVELOPMENT | 4 | 148 | 0.000259 | 0.005356 |
| 224 | VASCULOGENESIS | 3 | 59 | 0.0002579 | 0.005356 |
| 225 | MALE SEX DIFFERENTIATION | 4 | 148 | 0.000259 | 0.005356 |
| 226 | CHONDROCYTE DIFFERENTIATION | 3 | 60 | 0.0002711 | 0.005509 |
| 227 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 7 | 616 | 0.0002684 | 0.005509 |
| 228 | POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 3 | 60 | 0.0002711 | 0.005509 |
| 229 | NEGATIVE REGULATION OF CELL CYCLE | 6 | 433 | 0.0002696 | 0.005509 |
| 230 | REPRODUCTION | 10 | 1297 | 0.0002764 | 0.005591 |
| 231 | HEART FORMATION | 2 | 12 | 0.0002804 | 0.005599 |
| 232 | MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 2 | 12 | 0.0002804 | 0.005599 |
| 233 | REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY | 2 | 12 | 0.0002804 | 0.005599 |
| 234 | RESPONSE TO LIGHT STIMULUS | 5 | 280 | 0.0002889 | 0.005745 |
| 235 | REGULATION OF SMOOTHENED SIGNALING PATHWAY | 3 | 62 | 0.0002988 | 0.005916 |
| 236 | REGULATION OF CELL ADHESION | 7 | 629 | 0.0003047 | 0.005981 |
| 237 | REGULATION OF BINDING | 5 | 283 | 0.0003035 | 0.005981 |
| 238 | GASTRULATION | 4 | 155 | 0.0003088 | 0.006038 |
| 239 | REGULATION OF CARTILAGE DEVELOPMENT | 3 | 63 | 0.0003133 | 0.006048 |
| 240 | REGULATION OF EPIDERMIS DEVELOPMENT | 3 | 63 | 0.0003133 | 0.006048 |
| 241 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 3 | 63 | 0.0003133 | 0.006048 |
| 242 | REGULATION OF GROWTH | 7 | 633 | 0.0003166 | 0.006087 |
| 243 | REGULATION OF CELL FATE SPECIFICATION | 2 | 13 | 0.0003309 | 0.006336 |
| 244 | REGULATION OF IMMUNE RESPONSE | 8 | 858 | 0.0003579 | 0.006825 |
| 245 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 3 | 67 | 0.0003757 | 0.007135 |
| 246 | NEGATIVE REGULATION OF JUN KINASE ACTIVITY | 2 | 14 | 0.0003856 | 0.007205 |
| 247 | POSITIVE REGULATION OF MEIOTIC CELL CYCLE | 2 | 14 | 0.0003856 | 0.007205 |
| 248 | CELL MIGRATION INVOLVED IN GASTRULATION | 2 | 14 | 0.0003856 | 0.007205 |
| 249 | REGULATION OF SYNAPSE MATURATION | 2 | 14 | 0.0003856 | 0.007205 |
| 250 | UROGENITAL SYSTEM DEVELOPMENT | 5 | 299 | 0.0003905 | 0.007247 |
| 251 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 68 | 0.0003925 | 0.007247 |
| 252 | POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 3 | 68 | 0.0003925 | 0.007247 |
| 253 | HEART DEVELOPMENT | 6 | 466 | 0.000399 | 0.00731 |
| 254 | NEGATIVE REGULATION OF CELL DEATH | 8 | 872 | 0.0003989 | 0.00731 |
| 255 | REGULATION OF EPITHELIAL CELL MIGRATION | 4 | 166 | 0.0004006 | 0.00731 |
| 256 | REGULATION OF MITOTIC CELL CYCLE | 6 | 468 | 0.0004082 | 0.00742 |
| 257 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 4 | 167 | 0.0004098 | 0.00742 |
| 258 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 5 | 303 | 0.000415 | 0.007484 |
| 259 | REGULATION OF PROTEIN BINDING | 4 | 168 | 0.0004192 | 0.007531 |
| 260 | APPENDAGE DEVELOPMENT | 4 | 169 | 0.0004287 | 0.007614 |
| 261 | LIMB DEVELOPMENT | 4 | 169 | 0.0004287 | 0.007614 |
| 262 | POSITIVE REGULATION OF CELL DEVELOPMENT | 6 | 472 | 0.0004271 | 0.007614 |
| 263 | REGULATION OF MESODERM DEVELOPMENT | 2 | 15 | 0.0004443 | 0.00786 |
| 264 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 4 | 171 | 0.0004482 | 0.007899 |
| 265 | PANCREAS DEVELOPMENT | 3 | 73 | 0.0004835 | 0.00849 |
| 266 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 7 | 684 | 0.0005044 | 0.008824 |
| 267 | REGULATION OF BMP SIGNALING PATHWAY | 3 | 77 | 0.0005654 | 0.009853 |
| 268 | REGULATION OF SECRETION | 7 | 699 | 0.000574 | 0.00993 |
| 269 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 17 | 0.0005739 | 0.00993 |
| 270 | EYE DEVELOPMENT | 5 | 326 | 0.0005788 | 0.009974 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | FRIZZLED BINDING | 7 | 36 | 8.491e-13 | 7.888e-10 |
| 2 | WNT PROTEIN BINDING | 6 | 31 | 4.184e-11 | 1.943e-08 |
| 3 | WNT ACTIVATED RECEPTOR ACTIVITY | 5 | 22 | 8.187e-10 | 2.535e-07 |
| 4 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 445 | 1.346e-09 | 3.126e-07 |
| 5 | ENZYME BINDING | 18 | 1737 | 3.37e-09 | 6.261e-07 |
| 6 | PROTEIN KINASE ACTIVITY | 12 | 640 | 4.777e-09 | 7.397e-07 |
| 7 | MAP KINASE ACTIVITY | 4 | 14 | 1.656e-08 | 2.197e-06 |
| 8 | RECEPTOR AGONIST ACTIVITY | 4 | 16 | 3.001e-08 | 3.485e-06 |
| 9 | MOLECULAR FUNCTION REGULATOR | 15 | 1353 | 4.56e-08 | 4.707e-06 |
| 10 | KINASE ACTIVITY | 12 | 842 | 9.876e-08 | 9.175e-06 |
| 11 | RECEPTOR ACTIVATOR ACTIVITY | 4 | 32 | 5.788e-07 | 4.48e-05 |
| 12 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 12 | 992 | 5.764e-07 | 4.48e-05 |
| 13 | G PROTEIN COUPLED RECEPTOR BINDING | 7 | 259 | 1.032e-06 | 7.375e-05 |
| 14 | RECEPTOR REGULATOR ACTIVITY | 4 | 45 | 2.351e-06 | 0.000156 |
| 15 | TRANSCRIPTION FACTOR BINDING | 8 | 524 | 1.134e-05 | 0.0007021 |
| 16 | BETA CATENIN BINDING | 4 | 84 | 2.869e-05 | 0.001666 |
| 17 | SIGNAL TRANSDUCER ACTIVITY | 13 | 1731 | 3.408e-05 | 0.00168 |
| 18 | KINASE BINDING | 8 | 606 | 3.222e-05 | 0.00168 |
| 19 | RECEPTOR BINDING | 12 | 1476 | 3.436e-05 | 0.00168 |
| 20 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 4 | 92 | 4.105e-05 | 0.001816 |
| 21 | PROTEIN DOMAIN SPECIFIC BINDING | 8 | 624 | 3.967e-05 | 0.001816 |
| 22 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 6 | 371 | 0.0001168 | 0.00493 |
| 23 | ENZYME REGULATOR ACTIVITY | 9 | 959 | 0.0001377 | 0.00556 |
| 24 | ADENYL NUCLEOTIDE BINDING | 11 | 1514 | 0.0002154 | 0.008339 |
| 25 | REGULATORY REGION NUCLEIC ACID BINDING | 8 | 818 | 0.0002594 | 0.00964 |
| 26 | CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY | 2 | 12 | 0.0002804 | 0.009647 |
| 27 | GAMMA CATENIN BINDING | 2 | 12 | 0.0002804 | 0.009647 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | ENDOCYTIC VESICLE MEMBRANE | 6 | 152 | 7.305e-07 | 0.0004266 |
| 2 | EXTRACELLULAR MATRIX | 8 | 426 | 2.482e-06 | 0.0007248 |
| 3 | PROTEINACEOUS EXTRACELLULAR MATRIX | 7 | 356 | 8.424e-06 | 0.00164 |
| 4 | ENDOCYTIC VESICLE | 6 | 256 | 1.479e-05 | 0.002159 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | hsa04310_Wnt_signaling_pathway | 42 | 151 | 1.418e-92 | 2.553e-90 | |
| 2 | hsa04916_Melanogenesis | 16 | 101 | 7.705e-27 | 6.935e-25 | |
| 3 | hsa04390_Hippo_signaling_pathway | 13 | 154 | 4.207e-18 | 2.524e-16 | |
| 4 | hsa04912_GnRH_signaling_pathway | 11 | 101 | 1.17e-16 | 5.263e-15 | |
| 5 | hsa04340_Hedgehog_signaling_pathway | 8 | 56 | 2.459e-13 | 8.853e-12 | |
| 6 | hsa04010_MAPK_signaling_pathway | 11 | 268 | 6.04e-12 | 1.812e-10 | |
| 7 | hsa04012_ErbB_signaling_pathway | 8 | 87 | 9.651e-12 | 2.482e-10 | |
| 8 | hsa04720_Long.term_potentiation | 7 | 70 | 1.157e-10 | 2.604e-09 | |
| 9 | hsa04971_Gastric_acid_secretion | 7 | 74 | 1.727e-10 | 3.453e-09 | |
| 10 | hsa04510_Focal_adhesion | 9 | 200 | 2.799e-10 | 5.038e-09 | |
| 11 | hsa04020_Calcium_signaling_pathway | 7 | 177 | 7.844e-08 | 1.284e-06 | |
| 12 | hsa04270_Vascular_smooth_muscle_contraction | 6 | 116 | 1.478e-07 | 2.218e-06 | |
| 13 | hsa04722_Neurotrophin_signaling_pathway | 6 | 127 | 2.532e-07 | 3.411e-06 | |
| 14 | hsa04380_Osteoclast_differentiation | 6 | 128 | 2.653e-07 | 3.411e-06 | |
| 15 | hsa04662_B_cell_receptor_signaling_pathway | 5 | 75 | 4.944e-07 | 5.933e-06 | |
| 16 | hsa04370_VEGF_signaling_pathway | 5 | 76 | 5.285e-07 | 5.945e-06 | |
| 17 | hsa04664_Fc_epsilon_RI_signaling_pathway | 5 | 79 | 6.417e-07 | 6.794e-06 | |
| 18 | hsa04914_Progesterone.mediated_oocyte_maturation | 5 | 87 | 1.039e-06 | 1.039e-05 | |
| 19 | hsa04970_Salivary_secretion | 5 | 89 | 1.164e-06 | 1.102e-05 | |
| 20 | hsa04540_Gap_junction | 5 | 90 | 1.23e-06 | 1.107e-05 | |
| 21 | hsa04660_T_cell_receptor_signaling_pathway | 5 | 108 | 3.035e-06 | 2.601e-05 | |
| 22 | hsa04114_Oocyte_meiosis | 5 | 114 | 3.96e-06 | 3.24e-05 | |
| 23 | hsa04014_Ras_signaling_pathway | 6 | 236 | 9.314e-06 | 7.039e-05 | |
| 24 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 5 | 136 | 9.385e-06 | 7.039e-05 | |
| 25 | hsa04910_Insulin_signaling_pathway | 5 | 138 | 1.008e-05 | 7.255e-05 | |
| 26 | hsa04062_Chemokine_signaling_pathway | 5 | 189 | 4.578e-05 | 0.0003169 | |
| 27 | hsa04620_Toll.like_receptor_signaling_pathway | 4 | 102 | 6.149e-05 | 0.00041 | |
| 28 | hsa04360_Axon_guidance | 4 | 130 | 0.0001575 | 0.001013 | |
| 29 | hsa04621_NOD.like_receptor_signaling_pathway | 3 | 59 | 0.0002579 | 0.001601 | |
| 30 | hsa04920_Adipocytokine_signaling_pathway | 3 | 68 | 0.0003925 | 0.002355 | |
| 31 | hsa04730_Long.term_depression | 3 | 70 | 0.0004274 | 0.002482 | |
| 32 | hsa04622_RIG.I.like_receptor_signaling_pathway | 3 | 71 | 0.0004456 | 0.002507 | |
| 33 | hsa04070_Phosphatidylinositol_signaling_system | 3 | 78 | 0.0005871 | 0.003203 | |
| 34 | hsa04972_Pancreatic_secretion | 3 | 101 | 0.001244 | 0.006585 | |
| 35 | hsa04670_Leukocyte_transendothelial_migration | 3 | 117 | 0.001897 | 0.009755 | |
| 36 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 2 | 42 | 0.003515 | 0.01757 | |
| 37 | hsa04962_Vasopressin.regulated_water_reabsorption | 2 | 44 | 0.003851 | 0.01874 | |
| 38 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 3 | 168 | 0.005256 | 0.02465 | |
| 39 | hsa04742_Taste_transduction | 2 | 52 | 0.005341 | 0.02465 | |
| 40 | hsa04151_PI3K_AKT_signaling_pathway | 4 | 351 | 0.006173 | 0.02778 | |
| 41 | hsa04740_Olfactory_transduction | 4 | 388 | 0.008731 | 0.03833 | |
| 42 | hsa04115_p53_signaling_pathway | 2 | 69 | 0.00924 | 0.0396 | |
| 43 | hsa04976_Bile_secretion | 2 | 71 | 0.009761 | 0.04086 | |
| 44 | hsa04520_Adherens_junction | 2 | 73 | 0.0103 | 0.04212 | |
| 45 | hsa04210_Apoptosis | 2 | 89 | 0.01502 | 0.06008 | |
| 46 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 2 | 95 | 0.01699 | 0.06649 | |
| 47 | hsa04110_Cell_cycle | 2 | 128 | 0.02962 | 0.1134 | |
| 48 | hsa04530_Tight_junction | 2 | 133 | 0.03178 | 0.1192 | |
| 49 | hsa04630_Jak.STAT_signaling_pathway | 2 | 155 | 0.04198 | 0.1542 | |
| 50 | hsa04810_Regulation_of_actin_cytoskeleton | 2 | 214 | 0.07424 | 0.2673 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RP11-736K20.5 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-330-5p;hsa-miR-590-3p | 13 | FZD4 | Sponge network | -1.12 | 0 | -0.757 | 0.18617 | 0.911 |
| 2 | RP11-175K6.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-590-5p;hsa-miR-98-5p | 15 | FZD4 | Sponge network | -0.575 | 0.00197 | -0.757 | 0.18617 | 0.797 |
| 3 | MAGI2-AS3 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-98-5p | 15 | FZD4 | Sponge network | -0.532 | 0.00099 | -0.757 | 0.18617 | 0.694 |
| 4 | RP11-1024P17.1 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429 | 11 | FZD4 | Sponge network | -0.177 | 0.33588 | -0.757 | 0.18617 | 0.686 |
| 5 | RP11-1101K5.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-3127-5p | 14 | FZD4 | Sponge network | -0.926 | 0.2253 | -0.757 | 0.18617 | 0.645 |
| 6 | TRHDE-AS1 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-92b-3p;hsa-miR-98-5p | 22 | FZD4 | Sponge network | -1.208 | 0.04058 | -0.757 | 0.18617 | 0.639 |
| 7 | ADIPOQ-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-590-3p | 16 | FZD4 | Sponge network | -0.771 | 0.3685 | -0.757 | 0.18617 | 0.618 |
| 8 | ADAMTS9-AS2 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-92b-3p;hsa-miR-98-5p | 23 | FZD4 | Sponge network | -0.668 | 0.037 | -0.757 | 0.18617 | 0.617 |
| 9 | MIR143HG |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-92b-3p;hsa-miR-98-5p | 25 | FZD4 | Sponge network | -0.86 | 0.00094 | -0.757 | 0.18617 | 0.604 |
| 10 | EMX2OS | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-454-3p;hsa-miR-590-3p | 21 | FZD4 | Sponge network | -0.677 | 0.02209 | -0.757 | 0.18617 | 0.585 |
| 11 | AL035610.1 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p | 19 | FZD4 | Sponge network | -1.553 | 0.00698 | -0.757 | 0.18617 | 0.581 |
| 12 | ADAMTS9-AS1 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-92b-3p;hsa-miR-98-5p | 25 | FZD4 | Sponge network | -0.962 | 0.04922 | -0.757 | 0.18617 | 0.572 |
| 13 | ALDH1L1-AS2 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-454-3p;hsa-miR-590-3p | 15 | FZD4 | Sponge network | 0.289 | 0.67904 | -0.757 | 0.18617 | 0.564 |
| 14 | RP11-384P7.7 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 18 | FZD4 | Sponge network | -1.959 | 2.0E-5 | -0.757 | 0.18617 | 0.558 |
| 15 | MIR143HG |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-589-5p;hsa-miR-590-3p;hsa-miR-590-5p | 11 | PRICKLE2 | Sponge network | -0.86 | 0.00094 | -1.203 | 0.01176 | 0.555 |
| 16 | LINC00702 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-25-3p;hsa-miR-32-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | FZD4 | Sponge network | -1.07 | 0 | -0.757 | 0.18617 | 0.55 |
| 17 | HOXB-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-429 | 14 | FZD4 | Sponge network | -1.937 | 0 | -0.757 | 0.18617 | 0.549 |
| 18 | MEG3 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-25-3p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-454-3p;hsa-miR-590-5p;hsa-miR-98-5p | 20 | FZD4 | Sponge network | -0.963 | 0 | -0.757 | 0.18617 | 0.539 |
| 19 | LINC00924 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p | 14 | FZD4 | Sponge network | -0.367 | 0.24609 | -0.757 | 0.18617 | 0.534 |
| 20 | PGM5-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-27a-3p;hsa-miR-324-3p | 13 | FZD4 | Sponge network | -2.259 | 0.00169 | -0.757 | 0.18617 | 0.53 |
| 21 | RP11-166D19.1 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-32-5p;hsa-miR-454-3p;hsa-miR-590-3p | 11 | FZD4 | Sponge network | -0.49 | 0.00576 | -0.757 | 0.18617 | 0.523 |
| 22 | LINC00968 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-324-3p;hsa-miR-590-3p;hsa-miR-590-5p | 14 | FZD4 | Sponge network | 0.742 | 0.04551 | -0.757 | 0.18617 | 0.52 |
| 23 | AGAP11 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-590-5p | 18 | FZD4 | Sponge network | -1.402 | 0 | -0.757 | 0.18617 | 0.513 |
| 24 | RP11-92A5.2 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p | 14 | FZD4 | Sponge network | -1.261 | 0.13256 | -0.757 | 0.18617 | 0.487 |
| 25 | AC108142.1 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 11 | FZD4 | Sponge network | -0.622 | 0.11008 | -0.757 | 0.18617 | 0.482 |
| 26 | LDLRAD4-AS1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-500a-5p;hsa-miR-589-5p;hsa-miR-590-3p | 10 | PRICKLE2 | Sponge network | -4.332 | 0 | -1.203 | 0.01176 | 0.481 |
| 27 | RP11-180N14.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-98-5p | 14 | FZD4 | Sponge network | -1.548 | 0 | -0.757 | 0.18617 | 0.481 |
| 28 | RP11-597D13.9 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | PRICKLE2 | Sponge network | -3.183 | 0 | -1.203 | 0.01176 | 0.478 |
| 29 | MIR497HG | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-590-5p | 13 | FZD4 | Sponge network | -0.667 | 0.00055 | -0.757 | 0.18617 | 0.476 |
| 30 | DIO3OS | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-98-5p | 20 | FZD4 | Sponge network | -1.023 | 0.0019 | -0.757 | 0.18617 | 0.471 |
| 31 | AL035610.1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-589-5p;hsa-miR-590-3p | 10 | PRICKLE2 | Sponge network | -1.553 | 0.00698 | -1.203 | 0.01176 | 0.467 |
| 32 | HOXA-AS2 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-590-3p | 13 | FZD4 | Sponge network | -0.047 | 0.84015 | -0.757 | 0.18617 | 0.467 |
| 33 | AC003991.3 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-590-3p;hsa-miR-92a-3p;hsa-miR-92b-3p | 22 | FZD4 | Sponge network | -0.951 | 0.00515 | -0.757 | 0.18617 | 0.465 |
| 34 | RP11-384P7.7 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-21-5p;hsa-miR-576-5p;hsa-miR-589-5p;hsa-miR-590-3p | 11 | PRICKLE2 | Sponge network | -1.959 | 2.0E-5 | -1.203 | 0.01176 | 0.464 |
| 35 | RP11-38H17.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-25-3p | 10 | FZD4 | Sponge network | -3.06 | 0 | -0.757 | 0.18617 | 0.462 |
| 36 | C1orf132 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-589-5p;hsa-miR-590-3p | 11 | PRICKLE2 | Sponge network | -2.322 | 0 | -1.203 | 0.01176 | 0.451 |
| 37 | ADAMTS9-AS1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-576-5p;hsa-miR-589-5p;hsa-miR-590-3p;hsa-miR-590-5p | 12 | PRICKLE2 | Sponge network | -0.962 | 0.04922 | -1.203 | 0.01176 | 0.45 |
| 38 | TRHDE-AS1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-589-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | PRICKLE2 | Sponge network | -1.208 | 0.04058 | -1.203 | 0.01176 | 0.439 |
| 39 | AC004947.2 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-590-5p | 21 | FZD4 | Sponge network | -2.525 | 0 | -0.757 | 0.18617 | 0.437 |
| 40 | RP11-116O18.1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-589-5p;hsa-miR-590-3p;hsa-miR-590-5p | 15 | PRICKLE2 | Sponge network | -2.5 | 0 | -1.203 | 0.01176 | 0.435 |
| 41 | RP11-251M1.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-330-5p | 10 | FZD4 | Sponge network | -1.428 | 6.0E-5 | -0.757 | 0.18617 | 0.431 |
| 42 | RP11-116O18.1 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-98-5p | 20 | FZD4 | Sponge network | -2.5 | 0 | -0.757 | 0.18617 | 0.431 |
| 43 | RP11-276H19.1 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 14 | FZD4 | Sponge network | 0.128 | 0.62793 | -0.757 | 0.18617 | 0.423 |
| 44 | ACTA2-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-454-3p;hsa-miR-590-3p | 18 | FZD4 | Sponge network | -0.715 | 0.01146 | -0.757 | 0.18617 | 0.42 |
| 45 | AC004947.2 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-576-5p;hsa-miR-589-5p;hsa-miR-590-3p;hsa-miR-590-5p | 13 | PRICKLE2 | Sponge network | -2.525 | 0 | -1.203 | 0.01176 | 0.42 |
| 46 | RP11-822E23.8 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-330-5p | 17 | FZD4 | Sponge network | -2.084 | 0 | -0.757 | 0.18617 | 0.42 |
| 47 | PDZRN3-AS1 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p;hsa-miR-590-5p | 13 | FZD4 | Sponge network | 0.052 | 0.86474 | -0.757 | 0.18617 | 0.413 |
| 48 | LINC00504 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-330-5p;hsa-miR-361-5p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-589-5p;hsa-miR-590-3p | 13 | PRICKLE2 | Sponge network | -5.394 | 0 | -1.203 | 0.01176 | 0.408 |
| 49 | LINC01016 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | PRICKLE2 | Sponge network | -7.414 | 0 | -1.203 | 0.01176 | 0.391 |
| 50 | CTC-558O2.1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-330-5p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-590-3p | 12 | PRICKLE2 | Sponge network | -5.255 | 0 | -1.203 | 0.01176 | 0.381 |
| 51 | FZD10-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-590-3p;hsa-miR-98-5p | 17 | FZD4 | Sponge network | -0.576 | 0.01747 | -0.757 | 0.18617 | 0.379 |
| 52 | AC007743.1 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-429;hsa-miR-590-5p;hsa-miR-92b-3p | 11 | FZD4 | Sponge network | -0.687 | 0.0085 | -0.757 | 0.18617 | 0.375 |
| 53 | RP11-286B14.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-324-3p;hsa-miR-590-3p | 14 | FZD4 | Sponge network | 0.222 | 0.70649 | -0.757 | 0.18617 | 0.375 |
| 54 | LINC00648 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p | 13 | FZD4 | Sponge network | -1.323 | 0.05538 | -0.757 | 0.18617 | 0.375 |
| 55 | AF131215.2 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-454-3p;hsa-miR-98-5p | 13 | FZD4 | Sponge network | -0.283 | 0.21272 | -0.757 | 0.18617 | 0.375 |
| 56 | SOCS2-AS1 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-590-3p | 11 | FZD4 | Sponge network | -1.237 | 0 | -0.757 | 0.18617 | 0.368 |
| 57 | RP11-963H4.3 | hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-590-5p;hsa-miR-92b-3p | 11 | FZD4 | Sponge network | -0.509 | 0.41252 | -0.757 | 0.18617 | 0.367 |
| 58 | TPTEP1 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-454-3p;hsa-miR-590-3p | 15 | FZD4 | Sponge network | 0.291 | 0.27061 | -0.757 | 0.18617 | 0.366 |
| 59 | RP1-34H18.1 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p | 11 | FZD4 | Sponge network | -3.308 | 0 | -0.757 | 0.18617 | 0.365 |
| 60 | RP1-269M15.3 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-330-5p;hsa-miR-500a-5p;hsa-miR-590-3p | 10 | PRICKLE2 | Sponge network | -6.573 | 0 | -1.203 | 0.01176 | 0.352 |
| 61 | RP11-678G14.3 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-324-3p | 10 | FZD4 | Sponge network | -1.355 | 0.02597 | -0.757 | 0.18617 | 0.351 |
| 62 | AC141928.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-98-5p | 16 | FZD4 | Sponge network | -3.06 | 0 | -0.757 | 0.18617 | 0.344 |
| 63 | RP11-507B12.2 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-330-5p;hsa-miR-98-5p | 14 | FZD4 | Sponge network | -4.402 | 0 | -0.757 | 0.18617 | 0.343 |
| 64 | PWAR6 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-590-3p;hsa-miR-590-5p | 14 | FZD4 | Sponge network | -1.511 | 0 | -0.757 | 0.18617 | 0.341 |
| 65 | RP11-276H19.2 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-98-5p | 12 | FZD4 | Sponge network | 0.056 | 0.92103 | -0.757 | 0.18617 | 0.339 |
| 66 | LINC01085 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p | 10 | PRICKLE2 | Sponge network | -2.762 | 0 | -1.203 | 0.01176 | 0.338 |
| 67 | RP11-35J10.5 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-92b-3p | 13 | FZD4 | Sponge network | 0.278 | 0.73822 | -0.757 | 0.18617 | 0.333 |
| 68 | RP11-978I15.10 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-429 | 16 | FZD4 | Sponge network | -4.189 | 0 | -0.757 | 0.18617 | 0.332 |
| 69 | CTB-107G13.1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-590-3p | 10 | PRICKLE2 | Sponge network | -4.202 | 0 | -1.203 | 0.01176 | 0.323 |
| 70 | RP11-403B2.7 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-590-3p | 16 | FZD4 | Sponge network | -1.412 | 2.0E-5 | -0.757 | 0.18617 | 0.317 |
| 71 | C1orf132 |
hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-590-3p;hsa-miR-92a-3p;hsa-miR-98-5p | 17 | FZD4 | Sponge network | -2.322 | 0 | -0.757 | 0.18617 | 0.309 |
| 72 | RP11-597D13.9 |
hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-92a-3p | 18 | FZD4 | Sponge network | -3.183 | 0 | -0.757 | 0.18617 | 0.304 |
| 73 | LINC01085 |
hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p | 17 | FZD4 | Sponge network | -2.762 | 0 | -0.757 | 0.18617 | 0.298 |
| 74 | CTB-107G13.1 |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-590-3p | 14 | FZD4 | Sponge network | -4.202 | 0 | -0.757 | 0.18617 | 0.291 |
| 75 | RP11-115D19.1 |
hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-576-5p;hsa-miR-590-3p | 10 | PRICKLE2 | Sponge network | -5.233 | 0 | -1.203 | 0.01176 | 0.291 |
| 76 | CTD-3247F14.2 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-324-3p;hsa-miR-330-5p;hsa-miR-98-5p | 16 | FZD4 | Sponge network | -1.581 | 0.00115 | -0.757 | 0.18617 | 0.276 |
| 77 | HOXB-AS2 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-27a-3p;hsa-miR-324-3p | 10 | FZD4 | Sponge network | -3.109 | 0 | -0.757 | 0.18617 | 0.265 |
| 78 | LDLRAD4-AS1 |
hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-590-3p | 18 | FZD4 | Sponge network | -4.332 | 0 | -0.757 | 0.18617 | 0.258 |
| 79 | RP11-32B5.7 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-192-5p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-3127-5p;hsa-miR-590-3p | 15 | FZD4 | Sponge network | -2.009 | 1.0E-5 | -0.757 | 0.18617 | 0.255 |
| 80 | RP11-680F20.6 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-27a-3p | 10 | FZD4 | Sponge network | -5.623 | 0 | -0.757 | 0.18617 | 0.251 |